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The healthy endometrium has the unique capacity of shedding and regenerating its functional 
layer once every menstrual cycle, under the regulation of hormones, progenitor cell 
populations and inflammatory mediators. Thanks to this meticulously timed cycle the uterus 
is regularly renewed in preparation for blastocyst implantation. However, if any of these 
factors are perturbed, the result may be endometrial disorders with intrauterine scar 
formation, dysregulated proliferation and heavy menstrual bleeding. This PhD project 
addresses the interplay of these factors specifically within the endometrial stromal 
compartment in ensuring healthy endometrial regeneration and homeostasis, thereby 
investigating future therapeutic targets for benign gynecological disorders. Cells and tissue 
from endometrial biopsies and bone marrow aspirate were studied using multiple cellular and 
molecular techniques. Stromal cells have been characterized in terms of their phenotype, their 
transcriptome and their ability to immunomodulate, providing a starting point for future 
endometrial stromal cell therapy development. 
 
In study I, the transcriptional profile of progesterone receptor modulator associated 
endometrial changes (PAEC) was studied in women with three months of continuous 
mifepristone treatment to understand the future implications of PAEC and the safety of long-
term mifepristone use. Our microarray findings indicate that progesterone withdrawal and 
unopposed estrogen surge alter the endometrial structural organization and extracellular 
matrix composition, particularly affecting the stromal compartment in the tissue. No 
differentially regulated genes were involved in endometrial-cancer associated pathways. 
 
In study II, endometrial stromal cells (eSCs) were characterized in terms of their phenotype, 
immunomodulation and tumorigenicity for early pre-clinical cell therapy development. eSCs 
demonstrated a mesenchymal stromal cell (MSC) surface marker profile and multipotency, 
while retaining chromosomal stability and showing no tumorigenicity after in vitro 
expansion. When stimulated with pro-inflammatory cytokines, eSCs presented with an anti-
inflammatory phenotype and secreted immunomodulatory factors, but did not express human 
leukocyte antigen class II on their cell surface. eSCs suppressed CD4+ T cell proliferation 
and activation while significantly modulating their differentiation state, upregulating CD4+ 
effector memory T cells.  
 
The cellular diversity within the endometrial functional layer’s stromal compartment was 
explored in study III using single cell RNA sequencing. Different computational tools and 
an external dataset were used for analysis and validation. The study revealed diverse stromal 
subsets with transcriptional profiles representing different stromal activation states and 
niches important in wound healing, regeneration and immunomodulation. Several of these 
stromal transcriptional profiles could be validated in placenta derived decidua, suggesting 
the transcriptional profiles can withstand cycle changes and placentation. 
 
In study IV we determined the effects of blood exposure on bone marrow (BM) MSC 
viability and immunomodulatory functions, exposing BM MSCs to human blood products in 
vitro and evaluating their interactions with complement and the peripheral immune 
repertoire. Plasma exposure induced lysis of BM MSCs, while surviving BM MSCs had C3c 
bound to their surface. The MSC secretome reduced monocyte number and recruitment with 
many remaining monocytes skewed towards a classical, anti-inflammatory phenotype. 
Frequencies of immune modulating myeloid derived suppressor cells (MDSCs), both 
monocytic and polymorphonuclear, were also increased in response to BM MSCs. These data 
indicate that MSCs rapidly die once exposed to blood, but can still exert an anti-inflammatory 
response through the skewing of monocytes and upregulation of MDSCs. We hypothesize 
that this shift in the peripheral repertoire indirectly regulates adaptive immune cells’ response 
to the long-term tolerogenic effect seen after MSC intravenous infusion. 
 
In summary, endometrial regeneration is tightly regulated by hormones, immune cells and 
their interactions with stromal cells. Our research has provided new, detailed information on 
the stromal compartment by demonstrating there are multiple stromal subsets with different 
transcriptional profiles, presumably fulfilling multiple roles. Furthermore, eSCs have the 
ability to respond to inflammatory cues, as well as directly and indirectly modulating immune 
cells through their secretome. Additionally, BM MSCs exposed to blood can modulate the 
innate immune response even after cell death due to their release of soluble factors which 
induce an anti-inflammatory monocyte phenotype which lasts beyond their clearance from 
circulation. We conclude that stromal cells from different tissues have exceptional regulatory 
capacities in tissue homeostasis, inflammation and healing. 
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1 INTRODUCTION 
 
Endometrial regeneration, spontaneous decidualization and menstruation are a unique 
evolutionary adaptation which humans share with few other mammals, specifically apes, 
monkeys, elephant shrews and select bats (1). The endometrium undergoes approximately 
450 regenerations in a woman’s reproductive lifetime demonstrating a timely, hormonally 
controlled tissue turnover not observed in any other system (2). Despite this, little attention 
has been given to the endometrium either by the field of gynecology, or by the greater 
scientific community, as an in vivo model for inflammation and wound healing. While the 
underlying reasons for this are unclear, it is likely influenced by a combination of societal 
factors, which ultimately result in research concerning women’s benign gynecological 
disorders being overlooked and underfunded. In a similar thread, research on the 
endometrium has more frequently focused on the role of the endometrium in the context of 
embryo implantation, prioritizing the decidualization and placentation processes over 
regeneration (3-5). Although much progress has been made in recent decades, with the 
integration of high throughput molecular techniques in the field, many questions remain 
unanswered concerning human endometrial tissue complexity, and the mechanisms 
controlling menstruation and endometrial regeneration. More basic research is needed to 
explain the role of immune, stromal, epithelial and vascular cell crosstalk in regulating 
endometrial regeneration. To fully grasp benign endometrial disorders such as Asherman’s 
syndrome and heavy menstrual bleeding, an understanding of healthy tissue homeostasis at 
the beginning of the cycle is required.  
 
My PhD aims to provide a clearer understanding of the cellular composition in the 
proliferative phase endometrium. I have sought to determine the cell diversity, lineage, cell 
surface expression and molecular expression of different cell types within the stromal 
compartment. Emphasis has been placed on stromal subsets from the endometrial 
functionalis, their potential as a novel cell source for cellular therapy and their role in 
endometrial tissue homeostasis and pathophysiology. I have also taken a broader approach 
to cell therapy, specifically looking into bone marrow mesenchymal stromal cell mode of 





1.1 ENDOMETRIAL MORPHOLOGY 
 
The mucous lining of the uterus is collectively referred to as the endometrium and is 
composed of two layers: the basalis and the functionalis. The functionalis is the superficial 
layer where growth, deterioration and shedding is hormonally regulated by the hypothalamic-
pituitary-ovarian axis during the menstrual cycle (on average between 21-35 days) (6). 
Following menstruation, the functionalis regenerates from the basalis. Commonly this 
growth cycle is divided into the following stages: menstrual (standardized cycle day (CD) 1-
4), proliferative (CD 5-14) and secretory (CD 14-28) (5). Established cell populations within 
the endometrium include luminal epithelial, glandular epithelial, stromal, vascular 
(endothelial, smooth muscle, mural) and leukocytes (monocytes, primarily macrophages 
subtype 2 [M2], dendritic cells and natural killer [NK] cells, eosinophils, neutrophils, T cells, 
B cells and mast cells) (7, 8). The stromal compartment makes up the largest portion of the 
tissue and is covered by luminal epithelium. Tubular glands reach up from the basalis to the 
surface of the functionalis and are lined by glandular epithelium. Spiral arteries ensure blood 
supply to the tissue (9). The leukocytes are predominantly found in the stromal compartment 
and vary in distribution and abundance throughout the hormonal cycle with varying degrees 
of activation (10). The endometrium is a tissue which combines autocrine signaling, dynamic 
leukocytes and a highly responsive somatic cell population to ensure a meticulously timed 
menstrual cycle.  
 
1.2 HORMONAL REGULATION OF THE MENSTRUAL CYCLE 
 
The menstrual cycle runs parallel to the ovarian cycle and can be divided into three phases: 
the proliferative phase, which corresponds to the ovarian follicular phase; the secretory phase, 
which corresponds to the ovarian luteal phase; and the menstrual phase (depicted in Figure 
1). In the proliferative phase, primary follicles in the ovary start producing 17β-estradiol (E2) 
leading to the proliferation of epithelial, vascular and stromal cells, while new extracellular 
matrix (ECM) is laid down resulting in thickening of the endometrial tissue. Ovulation occurs 
midcycle, approximately CD 14, which is followed by the secretory phase. During the 
secretory phase, under the influence of pregn-4-ene-3,20-dione (progesterone; P4) produced 
in the corpus luteum, the endometrium undergoes functional differentiation with glands 
taking on a tortuous shape and increasing their secretion of glycoproteins (11, 12). P4 peaks 
in the mid-secretory phase leading to stromal decidualization; meaning transformation of 
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stromal cells from an elongated fibroblast morphology to a larger polygonal epithelioid 
shape. These changes are modulated by decidualization/ progesterone-dependent proteins 
and polysaccharides including: prolactin, glycogen, tissue factor (TF), insulin-like growth 
factor-binding protein 1, forkhead box o1 and cyclic adenosine monophosphate (12-15). In 
the absence of fertilization and embryo implantation the corpus luteum regresses and P4 
levels drop (6). While the hormone levels decrease, the endometrium sheds itself with 
enhanced apoptosis within the epithelial compartment (16). At the same time there is an 
increase of all leukocytes just before menstruation, which are reported to constitute 40% of 
all cells in the stroma (10, 17, 18). All cell populations in the endometrium are responsive to 
hormonal cues, yet it is within the stromal compartment that the greatest changes in cell cycle, 
cell function and morphology are observed. Aside from hormonal regulation, there are other 
mechanisms in place e.g. wound healing, which enable successful initiation of continued 
cycling.  
 
Figure 1: Human menstrual cycle 
Schematic diagram of the endometrium during the menstrual cycle, illustrating the physiological changes seen 
in menstruation, proliferative phase and secretory phase under estrogen and progesterone control. Figure 
reproduced with permission from Biorender. 
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1.3 THE INFLAMMATORY EVENTS OF ENDOMETRIAL BREAKDOWN 
AND REPAIR 
 
Inflammation is an unspecific response by the immune system to a foreign stimulus which 
eliminates infection or repairs injured tissue to restore homeostasis (12). The menstrual cycle 
can be classified as a series of contained inflammatory events spanning from tissue 
breakdown and repair in menstruation/ regeneration to tolerance/ rejection in decidualization 
and implantation (19). Hormonal and inflammatory regulation of the menstrual cycle are 
tightly interwoven (19), however the precise cascade of events controlling menstruation and 
repair is still an active field of research. 
 
Menstruation is initiated by the withdrawal of P4 from the endometrial vasculature and 
perivascular stroma by indirect activation of nuclear factor kappa B (NF-κB) pathway at the 
end of the secretory phase (20). Inflammatory events including the release of chemokines, 
cytokines, growth factors, lipid mediators, complement and prostanoids (prostaglandins and 
prostacyclins) orchestrate the activation and migration of immune cells to the endometrium 
(12). Simultaneously, stromal cell adhesion properties are altered and an increase in vascular 
permeability and vasodilation in the spiral arterioles enables endometrial shedding and 
vascular remodeling. Neutrophils are amongst the first immune cells recruited via the spiral 
arterioles. Tissue breakdown is led by focal activation of proteolytic matrix metalloproteases 
(MMPs) degrading ECM components and basement membrane (20). Depending on the 
microenvironment different neutrophil granules are released e.g. MMP9, proteinase 3 and 
elastase (20). These changes activate latent pro-inflammatory mediators including tumor 
necrosis factor alpha (TNFα), interleukin (IL)1β and recruit monocytes to the site of injury, 
polarizing them towards an macrophages subtype 1 (M1) phenotype (20). 
 
Towards the end of menstruation, the combined clotting system of platelet aggregation, fibrin 
deposits and thrombi formation begin hemostasis and damaged blood vessels contract (21). 
The subsequent release of growth factors and TF initiate wound healing and angiogenesis 
(21). Anti-inflammatory lipoxins contribute to the neutrophil clearance by inducing 
apoptosis. This is accompanied by phagocytosis of tissue debris and apoptotic neutrophils. 
Macrophages sense apoptotic cells in their environment adjusting their phenotype to M2 and 
releasing anti-inflammatory IL10, transforming growth factor beta 1 (TGFβ1) and further 
lipid mediators(12)(see Figure 2).  
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Menstruation can also be pharmaceutically induced by the administration of a progesterone 
agonist e.g mifepristone delivered during the mid-luteal phase. In animal models, this 
provides a suitable model to study inflammatory events in spontaneous menstruation (22). 
Although the menstrual cycle is frequently viewed as a series of consecutive steps, menstrual 
and proliferative phases are not absolute as tissue breakdown and regeneration occur in 
parallel at different foci (23). Thus, inflammatory mediators involved in tissue breakdown 
are also important regulators in ensuing tissue repair and data from these stages should be 




Figure 2: Inflammatory events in menstruation and regeneration   
Schematic diagram of inflammatory mediators and immune cells involved in endometrium breakdown and 
repair. Abbreviations: (P4) Progesterone; (ECM) extracellular matrix, (MMP) matrix metalloproteases. 
Diagram was created with BioRender adapted from Evans and Salamonsen. Rev Endocr Metab Disord, (2012) 
13:277–288. 
 
1.3.1 INFLAMMATORY MEDIATORS  
 
Several inflammatory mediators are essential for inflammation regulation in tissue 
breakdown and repair and contribute to the feedback loop controlling the menstrual cycle. 
Prostaglandin (PG) is an important mediator in inflammation and wound healing. In the 
endometrium, P4 inhibits PG synthesis by the suppression of cyclooxygenase 2 (COX2) and 
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induction of PG dehydrogenase. When P4 levels drop during the late secretory phase, COX2 
levels rise in stromal, epithelial and perivascular cells with increased PG synthesis (20). PGs 
contribute to vasodilation and smooth muscle contractions which aids in the shedding of 
decidualized tissue at menstruation (12). Furthermore, PGE2 increases IL6 and IL8 
expression via  PGE2 and PGE4 receptor indirectly contributing to leukocyte recruitment and 
edema formation (24). With respect to tissue repair, PGE2 increases the expression of growth 
factors specifically involved in angiogenesis, such as adrenomedullin, vascular endothelial 
growth factor (VEGF) and connective tissue growth factor (12). Lipid and protein mediators 
have been identified as possible contributors to tissue repair due to their ability to inhibit 
leukocyte function and pro-inflammatory cytokine secretion (25). Hofer et al. identified 
lipoxins as amongst the most abundant metabolites of arachidonic acid breakdown in 
menstrual blood. Arachidonic acid is a precursor to PGs (26).  
 
Pro-inflammatory cytokines associated with menstruation and orchestrating the initial tissue 
breakdown include TNFα, interferon gamma (IFNγ) and IL1β. Parallel to the increase in 
apoptosis seen towards the end of the secretory phase and during menstruation TNFα levels 
progressively increase during the secretory phase and reach a maximum concentration at 
menstruation (27, 28). IL6 is a cytokine produced by stromal cells, endothelial cells and 
immune cells. IL6 is produced in damaged/ activate endometrial stromal cells (eSCs) via toll-
like receptors (TLR) signaling and is important for subsequent immune cell recruitment and 
later tissue homeostasis. There is no conclusive data on whether IL6 is regulated by E2 or P4 
in eSCs however IL6 secretion is dose dependently stimulated by IL1β and the combined 
expression of IFNγ and TNFα (29). Thus, IL6 contributes to menstrual shedding directly or 
by modulating other cytokines and immune cells (30). IL10 is an anti-inflammatory cytokine 
secreted by macrophages to encourage wound healing, lower concentrations of systemic and 
tissue level IL10 have been measured in several benign gynecological disorders compared to 
healthy controls (31, 32). 
 
1.3.2 MONOCYTES AND MACROPHAGES  
 
Monocytes make up 10% of all circulating leukocytes and are recruited to an injury site 
during inflammation (33). As the precursors to macrophages and dendritic cells their cell fate 
is central to controlling inflammation. They can generally be classified into three subsets 
based on their cell surface markers: classical/ inflammatory (CD14+CD16-), non-
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classical/anti-inflammatory (CD14-CD16+) and the intermediate subset (CD14+CD16+ 
HLA II++) (33). Macrophages respond to environmental stimuli produced during injury or 
infection as well as adaptive immune cells. Macrophages can be broadly classified as pro-
inflammatory (M1) and anti-inflammatory (M2). M1 have anti-microbial activity, they 
secrete IFNγ and TNFα contributing to inflammation. M2 contribute to tissue repair and 
remodeling by secreting TGFβ1 and IL10 (33). 
 
Monocytes and macrophages are found at all stages of the menstrual cycle; however, an 
increase is seen prior to menstruation and during the early proliferative phase (20, 34, 35). 
Macrophages take part in phagocytic clearance of apoptotic cells during menstruation and 
are part of the tissue remodeling process during the proliferative phase, responding to E2 and 
glucocorticoids due to their cell surface expression of estrogen receptor beta and 
glucocorticoid receptor (GR) (12, 36, 37). Once macrophages have recognized peripheral 
phagocytosed apoptotic cells they change to an anti-inflammatory phenotype with the 
secretion of IL10, TGFβ, lipoxins and resolvins (38, 39). In a study looking at the correlation 
between cellular apoptosis and number of macrophages (CD68+) in human endometrium, 
the greatest number of macrophages and apoptosis was seen in the late secretory and early 
proliferative phases in line with the time when the tissue undergoes considerable tissue 
breakdown and repair (34). Less is known about the role of monocytes in endometrial repair, 
however higher expression of CD71, CD69 and CD54 on monocyte cell surface have been 
observed at this stage of the cycle. These markers are associated with proliferation, adhesion 
and activation suggesting their role in regulating and modulating the immune response(40). 
Furthermore, recent work has suggested monocytes are cleared by apoptosis once 
endometrial repair has been completed (41). Cousins et al. also identified several distinct 
monocyte/ macrophage populations which were putatively classified as classical monocytes, 
monocyte-derived macrophages and tissue-resident macrophages which all localized to areas 
of tissue breakdown and repair in the endometrium functionalis (41).  
 
M2-like activities are more abundant during the proliferative phase, in line with wound 
healing, remodeling and proliferation (42). In the context of endometriosis, M2 are most 
prevalent in proliferative endometriotic lesions. An in vivo study in mice has shown that M1 
obstruct lesion progression while M2 contribute to elevated unwanted endometrial stromal 
and epithelial proliferation. In another study, eutopic and ectopic endometrial stromal 
homogenates induced immunological tolerance of monocyte-derived macrophages in vitro, 
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polarizing the cells from M1 towards a M2 phenotype following co-culture. By neutralizing 
IL6 M2 polarization could be reversed(43).   
 
1.3.3 T CELLS  
 
T cell are a central component of the adaptive immune system and exert their action by cell 
mediated immunity; modulating other immune cells, endothelial cells and parenchymal cells 
(44). T cells are divided into two classes CD4+ T cells (T helper cells) which can activate 
macrophages and CD8+ T cells (cytotoxic T cells) which identify and kill infected cells. Via 
the T cell receptor (TCR), T cells can recognize antigen bound to the major histocompatibility 
complex (MHC). CD8+T cells recognize their cognate antigen presented by major 
histocompatibility complex (MHC) class I on antigen-presenting cells while MHC class II 
presents the cognate antigen to CD4+ T cells (45). Regulatory T cells (Tregs) are a T cell 
subset which counter acts T-cell mediated responses, with an overall immunosuppressive 
effect (44). Memory T cells are antigen-specific T cells which ensure the long-term recall of 
antigens and provide a rapid response on re-exposure, they are classified as long-lived 
circulating central memory (CM) T cell or tissue resident effector memory (EM) T cell (46, 
47).  
 
T cells are present throughout the menstrual cycle, however relative to other lymphocytes, 
they are considerably fewer in number (48). T cells can be found sparsely distributed in the 
epithelium and stroma, with lymphoid aggregates forming with B cells specifically during 
the secretory phase (49). Furthermore, unlike in peripheral blood, the ratio of CD4+ T cells 
and CD8+ T cells is inverted with more CD8+ T cells than CD4+ T cells. This is an 
interesting adaptation which hasn’t been investigated further in endometrium with regards to 
regeneration/ fibrosis. Presumably, this is a sign of increased immune activation indicative 
of changes in T cell migration and differentiation or an accumulation of CD8+ T cells in 
tissue (50). Interestingly, this is also seen in the mucosal lining of the intestine and has 
previously been explored in the context of liver fibrosis (51-53). The cytolytic potential of 
CD8+ T cells has been shown to be highest in proliferative phase endometrium and in 
endometrium from postmenopausal women, suggesting they are regulated by P4 and E2 (51). 
Although not specifically investigated within the proliferative phase endometrium, several 
human studies have demonstrated that the majority of CD4+ T cells and CD8+ T cells in the 
endometrium are activated (CCR5+) EM, a phenomenon also seen in placenta decidua (45, 
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52, 54). Particularly the CD8+ EM T phenotype has been investigated and discussed in the 
context of pregnancy, fetal tolerance and infection however what this means for endometrial 
regeneration still needs to be determined. 
 
 With regards to Tregs, there is conflicting data concerning their abundance and regulation 
during the menstrual cycle, with some research suggesting they are more abundant during 
menstruation while others say during proliferative phase (55, 56). This is partially due to the 
disparities in the cell surface markers used to characterize Tregs and the difficulty to 
distinguish between the two phases precisely (56). Considerably more research has 
investigated the role of Tregs in endometriosis, suggesting increased Tregs in endometriotic 
lesions compared to ectopic endometrium and eutopic endometrium (56, 57).  
 
1.4 ENDOMETRIAL REGENERATION AND THE PROGENITOR CELL 
NICHES 
 
Within 48 hours of menstruation, re-epithelialization of the injured tissue is initiated. 
Remaining luminal epithelium surface regions and epithelial glandular crypts heal, resealing 
the denuded stroma to re-establish mucosal homeostasis (23). As in other outward-facing 
mucosal linings, like the intestinal epithelium, the luminal epithelium provides an external 
barrier to invading pathogens (58). At menses the endometrium is thin (2-4 mm) with narrow, 
short glands. During the proliferative phase, the glands elongate and take on a coiled structure 
with interspersed stroma expanding simultaneously (5-11 mm) (23). Unquestionably, there 
is a close interaction between the stromal and epithelial cells during proliferation. Epithelial 
signals direct the hormonal stimulation of the stroma, thereby ensuring paracrine control of 
tissue growth (59). However, in the absence of hormonal support (oophorectomized) the 
endometrium is also able to heal itself without scarring, suggesting normal wound healing 
can override hormonal modulation to guarantee tissue repair when needed (60). 
  
It is generally accepted that the endometrium has a pool of progenitor cells that regulate its 
cyclical regeneration into epithelial, stromal and endothelial cells. This premise was first 
proposed by Chan et al. in 2004 when magnetic bead-selected epithelial cells 
(BEREP4+CD45- ) and stromal cells (BEREP4-CD45-) were grown at single cell density on 
fibronectin and a fibroblast feeder layer. By fulfilling the criteria of achieving colonies of 
varying sizes in both populations and their adhesion to plastic they proposed the existence of 
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putative endometrial progenitors (61). They hypothesized that approximately 0.22–0.52% of 
total epithelial and 1.25% of total stromal cells possess exceptional clonogenic potential in 
vitro. At this point, initial comparisons were made to mesenchymal stromal cells (MSCs) in 
other regenerative tissues (See Section 1.6 Mesenchymal Stromal Cells) (61). Following 
the release of the International Society for Cell and Gene Therapy’s (ISCT) MSC 
characterization guidelines, distinctions were made between the endometrial epithelial 
progenitor (EEP) seen in luminal and glandular epithelium and the stromal progenitor (ESP) 
found in the perivascular environment of the stromal compartment (62) (see Figure 3). For 
clarification purposes, unspecific endometrial stromal cells (bulk) will be referred to as eSCs 




Figure 3:  Endometrial progenitor environments involved in tissue regeneration  
Two thirds of the endometrium make up the functionalis and one third the basalis. Glandular epithelium extends 
from the base of the basalis to the top of the functionalis where the luminal epithelium covers the stroma. A The 
endometrial epithelial niche, containing epithelial progenitor cells (dark pink) and epithelial cells contributing 
to re-epithelization. Within the stromal compartment the vasculature is surrounded by endothelial cells and 
perivascular cell (mural cells and smooth muscle cells) and endometrial progenitor stromal progenitor cells, this 
constitutes the B Endometrial perivascular environment. The diagram was created with BioRender. 
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1.4.1 PERIVASCULAR ENVIRONMENT 
 
Early work aimed at drawing comparisons between ESPs and MSCs. Expanded ESPs 
presented the same cell surface expression proposed by the ISCT for MSCs: positive for 
CD90+, CD73+, CD105+ (> 95%) and negative for CD45-, CD34-, CD14-, CD19- and 
human leukocyte antigen class II (HLA class II; < 2%) (63). However, these surface markers 
are equally expressed on fibroblasts while CD73 has been shown to be upregulated on the 
stromal cell surface once expanded on plastic in vitro and as such may be a marker enhanced 
by these culture conditions (64). Consequently, it is difficult to distinguish ESPs from the 
greater eSCs on the basis of cell surface expression alone (65). Furthermore, it can be 
assumed that long-term expansion of progenitor cells outside of their in vivo niche, may lead 
to their terminal differentiation. To establish a hierarchy within the stromal compartment i.e. 
to distinguish between fibroblasts, transit amplifying cells and progenitor cells more specific 
markers are required. 
  
The current commonly applied marker combination is CD146+ and platelet-derived growth 
factor receptor ß (PDGFRß+), which identifies a perivascular population in vivo (63, 66, 67). 
It has been proposed that in vitro expanded or fresh flow cytometry sorted stromal cells 
expressing CD146+ PDGFRß+ identifies ESPs, CD146- PDGFRß+ fibroblasts and CD146+ 
PDGFRß- endothelial cells (67). As a follow up, Spitzer et al. performed a microarray 
analysis comparing gene expression between fibroblasts and ESPs, revealing differentially 
regulated genes associated with Notch1, TGFß1, Insulin-like growth factor 1, sonic 
hedgehog, and G-protein-coupled receptor, encouraging the premise of two distinct stromal 
profiles. Sushi domain containing 2 (SUSD2) has been proposed as a single marker which 
can replace the CD146+ PDGFRß+ marker combination for ESPs (68). Although these 
markers have been able to distinguish a perivascular cell, there have been very few functional 
studies with rodents or human biopsies showing capacity for ESPs to differentiate down 
multiple endometrial lineages, and the ability to long-term self-renew (69). Ultimate proof of 
ESP multipotency would be their ability to produce a vascularized stroma in vivo with stromal 
decidualization following paracrine cues.  
 
With the field’s concentration on the endometrial perivascular environment and the ESPs, 
several queries still need to be addressed. Whether the perivascular environment is 
endometrium-specific with resident progenitors and whether these progenitor cells really 
show in vivo plasticity (70). It is unclear whether the in vitro phenotype of ESPs (induced 
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multi-lineage differentiation potential) translates to in vivo settings. Can the ESPs, thanks to 
their ubiquitous distribution, contribute to tissue repair/ regeneration by replacing cells 
following injury?  
 
Furthermore, the current marker combination used to isolate ESPs (CD146+ PDGFRß+) is 
not specific to stromal cells as these markers are also used for pericytes (mural cells and 
vascular smooth muscle cells)(71). It is important to distinguish between different cells in 
the perivascular environment in order to determine clear cell profiles and understand their 
specific role in regeneration. Guimarães-Camboa et al. explored the role of pericytes (mural 
cells and vascular smooth muscle cells) from multiple sources (heart, brain, skeletal muscle, 
and adipose) in an in vivo mouse model, showing that labeled pericytes did not differentiate 
or alter their cell identity and plasticity in aging or following injury. However, once expanded 
in vitro they presented an MSC phenotype (72). Thus, the pericyte/ ESP questions must  also 
be addressed (73),  whether ESPs are pericytes and in vitro expansion induces a misleading 
MSC-like phenotype (74). Equally interesting are studies on bone marrow (BM) MSCs which 
show that CD146+ cell surface expression is regulated by oxygen availability suggesting 
expression is related to perivascular location/ proximity to oxygenated blood and handling 
rather than cell plasticity (75). Consequently, ESPs need further characterization, specifically 
looking at the impact of niche environment and establishing functional assays to determine 
their role in regeneration.  
 
Overall, the heavy reliance on a single stromal progenitor within the perivascular 
environment has limited the understanding of the greater stromal compartment. It is highly 
likely that a heterogeneous stromal compartment ensures tissue regeneration with complex 
interactions between multiple stromal populations and immune cells as seen in other tissues 
e.g. lung, lymph node and prostate(76-78). 
 
1.4.2 EPITHELIAL STEM CELL NICHE 
 
Based on gland-regulated re-epithelization following menses, EEPs are thought to originate 
from the basalis functionalis interface. Unlike ESPs, long-term expansion of epithelial cells 
in monolayer culture is not possible, due to senescence and loss of polarity, without the 
contribution of niche factors or a feeder layer of heat-inactivated fibroblasts (79). In one of 
the first in vitro studies exploring EEPs, endometrial glands were stained for sry-box 
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transcription factor 9 (SOX9), β-Catenin and surface stage-specific embryonic antigen-1 
(SSEA-1/ CD15), all showing intense staining in the basalis tissue. Of the three proteins, 
SSEA-1 showed the highest expression in the epithelial glands. Further assays confirmed that 
SSEA-1 + flow cytometry sorted cells had higher telomerase activity and telomere length. 
The SSEA1+ fraction was also able to form larger and significantly more spheroids in 
MatrigelTM than the SSEA1- fraction. N-Cadherin (CHD2) has been identified as a further 
cell surface marker of endometrial epithelial cells with greater stem/ progenitor properties. 
Cells expressing N-Cadherin have been explored in vitro (2D clonogenicity and self-renewal 
assays and 3D gland-like structures), as well as through immunofluorescence in whole tissue 
sections looking at co-localization with Ki-67 and SSEA-1, showing these cells to be 
quiescent and overlapping with the SSEA-1+ population (80). Nevertheless, there haven’t 
been any functional studies determining their role relative to other epithelial cells in the 
glands, in terms of hierarchy and cellular organization in the gland. Based on the 
characterization of the intestinal epithelial lining and the existence of adult stem cells crypts 
the marker leucine-rich repeat-containing g-protein coupled receptor 5 (LGR5) was proposed 
as a further EEP marker due to its mesodermal origin (81). In situ hybridization has shown 
LGR5 expression both in the luminal and glandular epithelium suggesting stem cells could 
be in both areas (82).  
   
In the last few years, advanced organoid cultures of the endometrial epithelium have been 
developed using human and rodent primary cells (83, 84). These 3D cultures with more 
defined in vitro conditions including MatrigelTM, different growth factors and signaling 
pathway mediators, can respond to hormonal cues (E2, P2, human chorionic gonadotropin, 
human placental lactogen and prolactin) and have long-term expansions capacity (> 6 
months) without evidence of genetic instability (83). Clonally expanded epithelial organoids 
can be derived from a single cell at different stages of the menstrual cycle and show bi-
directional differentiation capacity with ciliated and secretory subsets (83). In the 
pathological organoid models, organoids maintain the disease heterogeneity seen in 
endometriosis and endometrial cancer subtypes/ staging (85). 
 
Organoid studies have not fully clarified the cell diversity within the epithelial glands, nor 
established a stem cell hierarchy comparable with that seen in the intestinal epithelial crypts 
yet confirm the existence of endometrial epithelial stem cells (86). For the most part 
endometrial epithelial organoid studies have not been able to find a conclusive marker for 
EEPs. Turco et al. have readdressed SSEA-1 and SOX9 expression, and observed that cells 
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positive for these markers did not exclusively produce spheroids. Turco et al. proposed 
several new signature genes for EEPs including PROM1, AXIN2 and LRIG1, however protein 
confirmation in whole tissue sections couldn’t be performed due to lack of antibody 
specificity (83).  
 
Epithelial 3D cultures are an improvement on previous 2D cultures, however it is not certain 
whether the chemical conditions alone replace the stroma and immune cell niche. Self-
organizing stromal and epithelial cell organoids have been grown in scaffold-free agar inserts 
for 14 days but do not reassemble following passaging (79). As more epithelial stem cells 
and epithelial cells show evidence of de-differentiation from their terminal state by 
modulation of their niche (87, 88), it becomes clear that the interactions of the surrounding 
stroma provide more than just Wnt-signaling, bone morphogenic protein (BMP), BMP 
inhibitors and growth factors to the environment. In the intestine, the role of the mesenchyme 
in maintaining the stem cells is recognized, with fibroblasts, perivascular cells, smooth 
muscle cells and endothelial cells contributing soluble factors but also structural components 
(86). Multiple populations of stromal cells have been explored in rodent models to evaluate 
how their ablation/ modulation affects the epithelial cell niche and Wnt-signaling. Some of 
these stromal subsets are: FOXL1+, GLI1+ and CD34+GP38+aSMA– cells (89-91). 
Research on these protective stromal populations is preliminary yet a similar stromal 
population may exists in the endometrium where a SM22α+CD34+KLF4+ stromal 
population has already been identified and seen to participate in epithelial wound healing 
(92). In the past efforts have existed to identify a single stem cell to explain the scarless 
regeneration seen in the endometrium, however translational evidence from other organs and 
initial studies in the endometrium suggest a more complex interplay between different cell 
types, their plasticity and niche. 
 
1.5 BENIGN ENDOMETRIAL PATHOLOGIES  
1.5.1 HEAVY MENSTRUAL BLEEDING  
 
Heavy menstrual bleeding (HMB) is the most common menstrual disorder and a clear 
example of a pro-inflammatory disorder where the transition from controlled inflammation 
is impaired preventing swift coagulation and wound repair. Structural abnormalities in the 
uterus environment (polyps, adenomyosis and leiomyoma) can contribute to abnormal 
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bleeding patterns but are usually identified by ultrasound or magnetic resonance imaging. 
Unlike other benign gynecological disorders, unexplained HMB shows no apparent 
histological abnormalities, specifically with regards to glandular structures, distribution of 
glands or the number of arterioles in the tissue (12). This may suggest a disruption of the 
stromal compartment. HMB patients have significantly higher levels of TNFα protein 
expression in menstrual effluent than healthy women, while levels of MMP2 and MMP9 are 
significantly lower (93). Furthermore, HMB patients have increased collagenase and 
fibrinolytic activity while showing reduced expression of procoagulant factor and 
plasminogen activator inhibitor-1 (94, 95). Increased expression of COX1 and COX2 mRNA 
and PGE2 protein levels have also been observed in unexplained HMB, possibly explaining 
impaired clotting, stromal cell directed ECM remodeling and angiogenesis. There has also 
been evidence of lower hypoxia-inducible factor 1-alpha (HIFα) protein in women with 
HMB, as well as, its downstream targets VEGF and platelet factor 4 (96). No specific 
pathway has singularly been identified as responsible for HMB, thus multiple therapeutic 
approaches are being taken to improve clotting and limit inflammation and bleeding 
including: progesterone receptor modulators, synthetic androgens, non-steroidal anti-
inflammatory drugs, gonadotrophin-releasing hormone agonists/ antagonists, progestins and 
hormonal contraceptives (12).  
 
1.5.2 PROGESTERONE RECEPTOR MODULATOR ASSOCIATED 
ENDOMETRIAL CHANGES  
 
Since the discovery of the progesterone receptor (PR) in the 1970s, agonists/ antagonists of 
PR and synthetic progestins have been explored as therapeutic agents for benign gynecology 
conditions (97). The current set of ligands are classified as progesterone receptor modulators 
(PRM) which include several investigational compounds and clinically approved 
pharmaceuticals such as mifepristone, ulipristal acetate, asoprisnil, and vilaprisane. Although 
the precise mechanisms of action of PRMs remain unknown and may slightly vary depending 
on the specific compound, PRMs bind the PR thereby modulating the actions of native P4. 
Likewise, some PRMs modulate the estrogen receptor e.g. ulipristal acetate (98-101), while 
mifepristone has been seen to also modulate the GR (98-101). PRMs are of clinical interest 
in medical abortion, emergency contraception and management of symptomatic uterine 
fibroids. Ongoing research is also investigating their use as non-E2 daily oral contraceptives, 
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in slow-release contraceptive devices and therapeutically to induce amenorrhea or limit 
endometriosis and adenomyosis(12).  
 
Mifepristone was the first PRM developed and has a two times greater affinity to PR than P4 
(102). The effect of mifepristone on the reproductive system is dose, cycle-day and frequency 
dependent. At a high concentration of 10 mg/day follicular development is inhibited by the 
systemic suppression of gonadotrophins and E2 secretion is significantly reduced (12, 103). 
At a lower dose of 2 mg/day ovulation is delayed without preventing follicular development 
with disruption to the regeneration/ differentiation of the endometrial functionalis. 
Endometrium E2 levels are comparable to those seen in the mid-proliferative phase (12, 103). 
Consequently, during long-term low-level use of mifepristone the endometrium is exposed 
to unopposed E2 levels, an environment not seen under physiological conditions. 
  
Uterine leiomyoma or fibroids are benign tumors derived from a single myocyte in the 
myometrium. Although most fibroids do not present with symptoms, they can have a severe 
impact on quality of life. The most common symptom is HMB, followed by pelvic pressure 
and pain. Women can also suffer from infertility due to the fibroid’s intra-cavitary location 
where they exerting pressure on the endometrium (104). Oral administration of PRMs 
reduces HMB and may also reduce fibroid size (98-100), however, long-term continuous 
PRM use causes specific non-physiological endometrial changes in up to 60% of treated 
women (100). Importantly, these changes are reversible with the termination of treatment 
(100). Pathologists have called these changes progesterone receptor modulator associated 
endometrial changes (PAEC). Histological characteristics include: extensive dilated cystic 
glandular formations with watery content, inactive glands with low mitotic or quiescent 
epithelial cells, densely packed stroma not comparable to decidualization and an altered 
appearance of the spiral arteries (103, 105, 106). A further concern has been that long-term 
exposure to PRMs may cause excessive thickening of the endometrial stroma (hyperplasia) 
through uninterrupted E2 exposure, resulting in a pre-malignant phenotype seen in the 
fibroblasts. 
  
For the most part, pathologists have classified these changes as benign however there has 
only been limited molecular validation of this assessment (99, 107). For the most part, 
researchers have looked at the altered tissue physiology collectively (primarily by 
histological approaches) rather than looking at specific cellular processes or cell types. 
However, in one in vitro study the effects of E2 and P4 are inhibited by the addition of 
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ulipristal acetate to cell culture, which results in inhibition of pathways controlling 
cytoskeletal remodeling, cell migration and tissue reorganization (108). Additionally, 
Wilkens et al. reported that asoprisnil down-regulates the expression of genes associated with 
endometrial immune cell function in the stromal compartment, specifically downregulating 
IL15 and decreasing the abundance of uterine NK cells. Although opinions differ on the 
overall effect of PRMs on the tissue, the clinical concern remains, with current models of 
treatment employing an interrupted schedule with 12 weeks of treatment followed by 
withdrawal to allow endometrial shedding (12). As the use of PRMs extends beyond induced 
abortion, miscarriage, fibroid treatment and emergency contraception to possible regular 
contraception, there is a need to ensure the drug safety and understand how prolonged use 
may affect a complex tissue composed of multiple cell types and niches. 
 
1.5.3 ASHERMAN’S SYNDROME  
 
In Asherman’s syndrome (AS) scar tissue adhesions form between the uterine walls 
obstructing blastocyst migration and implantation. Adhesions can have a mixed composition 
containing endometrial, connective and muscular tissue which reveals the possibility of 
multiple cell compartments being affected (109). A grading system classifies the condition 
into degrees of severity (See Table 1) ranging from endometrium with thin adhesions in low 
grade AS, to extensive fibrosis of the endometrium basalis and myometrium with reduced 
vascularization in heavily affected patients. In the two most severe classifications patients 
experience disease reoccurrence after surgery and infertility. Importantly, due to the 
functional layer being non-responsive to E2 and P4 regulation, the menstrual cycle may cease 
to exist altogether (110). In the assisted reproductive technology setting, endometrial 
thickness is frequently used to determine clinical responsiveness to hormone replacement 
therapy. An atrophic endometrium with endometrial thickness ≤8 mm during the window of 
implantation may suggest impaired regeneration, presumably due to an inhibition of stromal 
expansion in the proliferative phase (111). Consequently, AS patients and repeated 
implantation failure (RIF) patients are considered for similar treatments targeting 
endometrial regeneration. 
 
Frequently, AS results from surgical trauma or chronic inflammation caused by infection e.g. 
genital tuberculosis or irradiation (112). However, idiopathic AS cases exist too (113). On a 
cellular level, the pathology of AS has not been determined however we hypothesize a 
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deregulated inflammatory and healing response in the menstrual cycle. Disruption to the 
functional and basal glands may also play a role in AS (114, 115). Likewise, a perturbed 
perivascular environment and vascular occlusion could limiting hormonally regulated 
stromal proliferation and angiogenesis (115). AS endometrium presents an altered stromal 
composition and ECM compared to healthy endometrium with upregulated expression of the 
proteases disintegrin and metalloproteinase domain-containing protein (ADAM)15 and 
ADAM17, as well as TGFβ1, SMAD family member 3 (SMAD3) and SMAD7 (116, 117).  
 
Fibrosis is the aberrant accumulation of myofibroblasts and ECM products leading to chronic 
scar formation (118). The emerging picture in fibrotic research suggests that chronic 
exposure to pro-inflammatory and pro-fibrotic cytokines, ECM deposition and aberrant 
healing may deregulate stromal cells and push them towards myofibroblast differentiation. 
This has been explored in numerous tissues, including skin (119) kidney (120) heart (121) 
and bone marrow (122). Taking this into consideration, it has been proposed that deregulation 
of inflammatory processes in the endometrial stroma are exacerbated in AS. The combination 
of initial uterine trauma and low E2 levels may contribute to fibrosis rather than replenishing 
the stroma with dysregulated eSCs exacerbating the condition and preventing regeneration 
(123, 124).  
 
Although adhesions and damaged functionalis can be removed via hysteroscopy, adhesions 
frequently reoccur (110). The current line of treatment is repeated hysteroscopies to clear the 
uterine cavity of scar tissue, followed by insertion of an intrauterine device and E2 treatment. 
As of recently, alternative/ supplementary treatments are being tested in vitro, clinically 
trialed and discussed. These include several anti-inflammatory/ regenerative therapies 
including angiogenesis promoting cell therapies (125), stromal cell therapies (126, 127), 
intra-uterine platelet rich plasma infusion (128), hyaluronic acid gel (129), intrauterine 
devices (E2) or insertion of an intrauterine balloon (130). 
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Table 1: Intrauterine adhesions classification system issued by the European 
Society of Gynecological Endoscopy (adapted from Yu et al., 2008) 
 
Grade Extent of Intrauterine adhesions 
I Thin or flimsy adhesions 
Easily ruptured by hysteroscope sheath alone 
Cornual areas normal 
II Singular dense adhesion 
Connecting separate areas of the uterine cavity 
Visualization of both tubal ostia possible 
Cannot be ruptured by hysteroscope sheath alone 
IIa Occluding adhesions only in the region of the internal cervical os 
Upper uterine cavity normal 
III Multiple dense adhesions 
Connecting separate areas of the uterine cavity 
Unilateral obliteration of ostial areas of the tubes 
IV Extensive dense adhesions with (partial) occlusion of the uterine cavity 
Both tubal ostial areas (partially) occluded 
Va Extensive endometrial scarring and fibrosis in combination with grade I or 
grade II adhesions 
With amenorrhea or pronounced hypomenorrhea 
Vb Extensive endometrial scarring and fibrosis 
In combination with grade III or grade IV adhesions with amenorrhea 
 
1.6 MESENCHYMAL STROMAL CELLS AND CELL THERAPY 
DEVELOPMENT  
1.6.1 MESENCHYMAL STROMAL CELLS  
 
MSCs were first reported in 1968 with the discovery by Friedenstein et al. that bone marrow 
aspirate contained fibroblast-like cells which could adhere to plastic, form colonies and 
differentiate into osteoblasts in vitro (131). However, since their discovery, cells fulfilling 
these basic criteria have been derived from numerous stromal compartments including 
adipose (132), umbilical cord (133) and placenta (134).  
 20 
  
As the number of MSC sources has grown, it has become clear that the initial characterization 
criteria apply to a heterogeneous cell population. Consequently, in 2005 the ISCT suggested 
nomenclature changes, advising to exchange the term mesenchymal stem cell for 
mesenchymal stromal cell (135). Amongst the different MSC sources, only a proportion of 
cells present self-renewal and multi-lineage differentiation potential as would be expected of 
a stem cell. Furthermore, the ISCT set criteria regarding MSC phenotype and function, 
defining an MSC as a cell, which adheres to plastic when cultured in vitro and upon induction 
can differentiate into adipocytes, osteoblasts and chondrocytes. Moreover, they have positive 
cell surface expression of CD73, CD90 and CD105 (> 95%), and are negative for the 
hematopoietic markers CD34, CD45, CD11, CD14, CD19 and HLA class II (< 2%). Changes 
in MSC guidelines have addressed some of the misunderstandings of the rapidly expanding 
field, however many remain. BM MSCs account for up to 0.01% of mononuclear cells. Thus, 
BM MSCs represent a rare fraction of cells, which are primarily studied in vitro following 
expansion, while less is known about their role in vivo (136). Additionally, in the rush to 
align different stromal cell sources with MSC criteria there is less focus on the molecular 
differences between these MSC populations. These molecular differences are presumably 
specific to a particular niche, function and organ, and thus warrant investigation. 
 
Clinical trial results suggest that MSCs participate in wound repair and tissue homeostasis 
by suppressing ongoing inflammatory processes and supporting endogenous repair 
responses, rather than directly replacing damaged tissue (137). Thus, researchers have 
focused on characterizing MSC immunomodulation, distinguishing between MSCs’ ability 
to sense their inflammatory environment and the effect MSCs have on specific immune cells 
through direct contact or their secretome.  
 
1.6.2 MESENCHYMAL STROMAL CELL IMMUNOMODULATION 
 
MSCs sense foreign DNA and pathogens through pathogen-associated molecular patterns 
(PAMPS) on their cell surface (138). As a consequence, they mediate chemokine and 
cytokine cascades initiating the inflammatory response and leukocyte recruitment in 
infection and wound healing. By extension, MSCs have the ability to respond to their 
inflammatory environment, changing their phenotype accordingly and secreting a battery of 
mediators specific to the milieu. It has been hypothesized that MSCs can be both “activated”  
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and “resting” (139) ( See Figure 4 for “activated” MSC immunomodulation). At “resting” 
state, MSC co-exist with leukocytes in the microenvironment conserving T and B cell 
quiescence and survival. They protect T cells from activation-induced death by down-
regulating fas cell surface death (FAS) receptors on their cell surface, as well as, the 
corresponding FAS ligand on T cells (140, 141).  
 
1.6.2.1 KEY SOLUBLE FACTORS 
When MSCs are exposed to pro-inflammatory cytokine licensing via IFNγ and tumor TNFα, 
MSCs shift to an immune-suppressive, “activated” phenotype secreting anti-inflammatory 
mediators including PGE2, IL6 and indoleamine 2,3-dioxygenase (IDO) (139, 142-144). 
These soluble factors are part of a greater feedback loop signaling to immune cells affecting 
their recruitment, proliferation, activation and differentiation(33).  
IDO is a catabolic enzyme that converts tryptophan to kynurenine. Increased secretion of 
IDO from MSCs accelerates the breakdown of tryptophan, reducing T cell proliferation as 
tryptophan is required for protein synthesis in cell metabolism, additionally IDO secretion 
has an anti-bacterial effect (145). MSCs constitutively secrete high levels of IL6, which upon 
co-culture with peripheral blood mononuclear cells (PBMCs) or exposure to pro-
inflammatory cytokines, is significantly elevated (146). Djouad et al. reported that IL6 levels 
correlated with the number of MSCs in culture and inversely correlated with IFNγ and TNFα 
detected in culture media (146, 147). IL6 has been shown to reverse dendritic cell maturation 
and inhibit T cell activation while inducing monocytes towards M2 differentiation (147). IL6 
production has also been linked to PGE2 secretion, with PGE2 inhibition reducing IL6 
secretion (147). Aggarwall et al. demonstrated that inhibition of PGE2 synthesis mitigated 
the immunosuppressive effects of MSCs in co-culture with PBMCs, increasing T and 
dendritic cells proliferation(143).  
MSCs also regulate their cell surface expression of HLA class I and II. At resting state MSCs 
have low HLA class I expression and low/ absent expression of HLA class II, however 
following IFNγ licensing MSCs upregulate HLA class I expression and induce HLA class II 
expression (62). With regards to HLA class II expression, differences have been observed 
between MSC sources. While seven days of IFNγ licensing was required for full surface 
expression of HLA class II in adult BM MSCs, only two days were needed for adult 
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MSCs(148). In other words, depending on the stromal source and developmental stage, HLA 
regulation can vary.  
Recently, MSC derived extravascular vesicles (eVs) including exosomes and micro-vesicles 
have been explored for their role in immunomodulation. eVs can be released from cells and 
contribute to intra-cellular communication by means of transferring protein, lipids and 
RNAs(149). eVs have also been shown to express TLR4 enabling them to respond to 
exogenous and endogenous signals (149). Much like MSCs, in an in vitro setting, eVs can 
inhibit T cell differentiation and induce Tregs while reducing IFNγ production (150, 151). 
eVs can also contribute to the induction of a M2 phenotype in monocytes and reduce levels 
of pro-inflammatory cytokines (IL1β, TNFα) (152).  
1.6.2.2 COMPLEMENT 
 
Complement is a part of the early innate immune response, and has been associated with 
antibody mediated transplant rejection and the removal of MSC from circulation in the 
context of the Instant Blood Mediated Inflammatory Reaction (IBMIR)(153). Complement 
activation can occur via three routes (classical, lectin or alternative). Each route results in 
multiple cleavage steps of complement component 3 (C3) into C3a and C3b and subsequent 
cleavage of C3b into iC3b and C3dg. These products are bound to the MSC surface and act 
as ligands recruiting leukocytes. Complement activation reduces infection by increasing the 
recruitment and activation of phagocytes, and can induce cell injury by the membrane attack 
complex (MAC) which disrupts the cell membrane(33). In clinical trials, higher levels of 
complement anaphylatoxins C3a were found in patients treated with an intravenous (IV) 
infusions of MSCs indicative of complement activation (154). Consequently, it has been 
hypothesized that in binding complement fragments to the cell surface of MSCs, MSCs may 
control and mediate leukocyte recruitment and their immunophenotype (155-157). This 
would explain, in part, how MSCs with bound C3 may indirectly suppress PBMC 
proliferation (158). Additionally, the binding of complement anaphylatoxins C3a and C3b 
via their receptors to the MSC surface has been shown to reduce the effect of oxidative stress 
on MSCs and enhance their anti-apoptotic mechanisms (159).  On the other hand, MSCs have 
been shown to express the complement inhibitors CD46, CD55 and CD59 on their cell 
surface, enabling them to partially limit activation (33).  
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 1.6.2.3 MESENCHYMAL STROMAL CELL MODULATION OF T 
CELLS  
 
An imbalance between the different effector T cells and Tregs contributes to autoimmune 
and inflammatory diseases, as well as to transplant rejection, making them important 
leukocytes to study with regards to MSC immunomodulation. Activated T cell proliferation 
is inhibited by MSC co-culture, affecting both CD4+ and CD8+ T cells (160-162). MSC-
mediated T cell inhibition has been associated with down-regulation of activation markers 
CD25, CD38, and CD69 on the surface of both CD4+ and CD8+ T cells (163). Furthermore, 
Groh et al. found that monocytes were required in the co-culture for MSC-induced CD4+ T 
cell suppression; this dependency was not seen when other lymphocytes were depleted e.g. 
B cells (160, 163). Several soluble factors have been associated with T cell proliferation 
inhibition by MSCs, with most studies agreeing on the roles of TGFβ1, PGE2 and IDO (161, 
162, 164-166). While IDO-mediated T-cell inhibition is MSC activation dependent, PGE2 
and TGFβ1 are constitutively secreted by MSCs, although further up-regulated by IFNγ and 
TNFα licensing (164, 165). Several studies have demonstrated that T cell proliferation 
inhibition is dose dependent, meaning relative to the number of MSCs in the co-culture and 
their secretory profile (162, 167). MSC co-culture induces cell cycle arrest at G0/G1 in the 
proliferation inhibited T cells but does not induce cell death, with similar effects on cell cycle 
seen in B cell MSC co-culture (160, 168, 169). Overall, these series of experiments suggested 
that MSCs of different origin can suppress T cell proliferation in a dose-dependent manner, 
with monocytes indirectly mediating the suppression through soluble factors. 
 
A handful of studies have studied the effect of MSCs on memory T cell differentiation. 
Krampera et al. demonstrated that MSCs inhibit both naïve and memory (antigen-
experienced) T cell responses to their cognate antigens, affecting cell proliferation, 
cytotoxicity (percentage of IFNγ producing CD8+ T cells was lower) and the number of 
target antigen-reactive T cells (170). In another study with MSCs derived from BM, placenta 
decidua and amniotic fluid, prior to co-culture the number of memory T cells was higher than 
the number of naïve T cells, however following the co-culture the proportions were reversed 
with naïve T cells significantly increased while the memory T cells decreased (161). 
Although there has been conflicting data concerning the effect of MSC co-culture on naïve 
T cells, several BM MSC studies demonstrate suppression of memory CD4+ T cell 
differentiation suggesting an overall effect of a more immune tolerant profile (166, 171). 
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MSC IL10 induction has been suggested to limit memory T cell differentiation specifically 
within the CD 4+ T cells (166). 
 
Tregs contribute to the maintenance of self-tolerance and regulation of autoreactive immune 
cells (172). Additionally, the frequency of circulating Tregs is considered a diagnostic and 
prognostic marker of outcome in transplantation research and Graft-versus-Host-Disease 
(GvHD) (173). Therefore, their induction from CD4+ T cells and CD8+ T cells, and 
proliferation has been studied in co-cultures with human MSCs (146, 161, 164, 174-176). 
MSCs in co-culture with PBMCs can induce the formation of Tregs 
(CD4+CD25HighFoxP3+) through cell to cell contact and soluble factors (146, 164, 174-
176). This is partially controlled through MSC secretory factors such as TGFβ1 and PGE2, 
however also by the indirect actions of monocytes and their secretory factors including 
CCL18 (146, 164).   
 
1.6.2.4 MESENCHYMAL STROMAL CELL MODULATION OF 
PERIPHERAL MONOCYTE SUBSETS  
 
MSCs promote the migration of monocyte progenies from the bone marrow to the inflamed 
tissue through the secretion of the chemokine (C-C motif) ligands, including monocyte 
chemoattractant protein-1 (CCL2/MCP-1), CCL3 and CCL12 (177). Monocytes respond to 
MSC derived IDO enzymatic activity by altering their phenotype to a IL10 secreting CD206+ 
M2-like macrophages (178). Additionally, anti-inflammatory M2 markers CD206, CD163 
and CD80 are upregulated on the cell surface of monocytes in MSC monocyte co-culture, 
suggesting a skewing of their phenotype (146). One of the soluble factors controlling 
monocyte phenotype is macrophage colony-stimulating factor (M-CSF), which is involved 
in the skewing of monocytes towards M2 macrophages (146). Similarly, IL6 is an important 
mediator in skewing monocytes to macrophage differentiation(179) At a gene level, MSC 
conditioned media stimulation of macrophages results in upregulation of genes associated 
with the M2 macrophage phenotype including CD163, GAS6, CCL18, PLTP (146). 
Interestingly, in mixed activated PBMC MSC co-cultures, removal of monocytes 
significantly reduces the overall immune suppressive effect of MSCs (146). 
 
MSCs can also directly modulate tissue resident macrophages skewing them from an M1 
towards M2 phenotype, with increased expression of CD206, CD163 and down-regulation 
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of CD86 so as to suppress local inflammation and support swift wound healing (146, 178, 
180-182). In MSC-macrophage co-cultures, activated MSCs and MSC-conditioned media 
reduces pro-inflammatory TNFα levels and cell surface expression of HLA class II, while 
increasing anti-inflammatory IL10. High levels of IL10 suppress neutrophil recruitment to 
the site of injury and effector T cell stimulation, thereby limiting oxidative damage and 
encouraging wound healing (183). Macrophage proliferation and migration is enhanced by 
MSC and MSC conditioned media indicating their role in wound clearance and repair. In 
mice, MSC derived PGE2 has also been shown to elevate IL10 macrophage secretion by 
binding to the EP2 and EP4 PG receptors on the macrophage cell surface (180).  
 
MSC- macrophage co-culture has been accompanied with increased phagocytic activity of 
macrophages, an adaptation important for infection clearance and resolution of inflammation 
(184, 185). Furthermore, in the context of IV infusion of MSCs, MSCs are suggested to be 
engulfed by phagocytic cells, triggering increased cell surface expression of CD163 and 
CD206 on monocytes, in line with an M2 phenotype (186). During engulfment, the MSCs 
appear to be regulating the immunophenotype as seen by increased IL10 and TGFβ1 
expression and reduced TNFα (187). Consequently, it has been hypothesized by Hoogduijn 
et al. that MSCs can even regulate monocytes once engulfed, altering the first responder’s 
immunophenotype at the site of inflammation (188).  
 
1.6.2.5 MESENCHYMAL STROMAL CELL MODULATION OF 
MYELOID DERIVED SUPPRESSOR CELLS  
 
Myeloid-derived suppressor cells (MDSC) are a immunosuppressive heterogenous group of 
immune cells from the myeloid lineage, although there is limited research on their 
interactions with MSC, a few studies suggest they have anti-inflammatory functions (33). 
MSCs derived growth regulated oncogene (GRO) chemokines stimulate a tolerogenic MDSC 
phenotype through the increased secretion of IL10 and IL4(189). Yen et al., demonstrated 
that MSC derived-hepatocyte growth factor (HGF) induces MDSC proliferation, which in 
turn contributed to CD4+ T cell proliferation suppression in vitro (190). HGF has previously 




Figure 4: Mesenchymal stromal cell anti-inflammatory immunomodulation of 
immune cells  
Activated mesenchymal stromal cells (MSC) secrete soluble factors and extracellular vesicles (eV) which 
regulate immune cells: effector T cells (CD4+ and CD8+), memory T cells, regulatory T cells (Treg), myeloid 
derived suppressor cells (MDSC), monocytes and anti-inflammatory macrophages (M2). Indirectly, MSCs 
induce immune cells to alter their phenotype and secrete further soluble factors. Abbreviations: (PGE2) 
prostaglandin E 2, (TGFβ1) transforming growth factor beta 1, (IDO) indoleamine 2,3-dioxygenase, (IL10) 
interleukin 10, (IL6) interleukin 6, (M-CSF) macrophage colony-stimulating factor, (MCP-1) monocyte 
chemoattractant protein-1, (CCL18) CC-chemokine ligand 18, (TNFα) tumor necrosis factor alpha, (IFNγ) 
interferon gamma, (M1) macrophage subtype 1. The diagram was created with BioRender.  
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1.6.3 MESENCHYMAL STROMAL CELL THERAPY  
 
MSCs are investigated as a cell therapeutic due to their immunomodulatory capacity, with 
232 clinical studies registered as active or completed on clinicaltrials.gov (May 7th, 2020), 
involving the search term “mesenchymal stromal cell”. MSCs were first applied as a cell 
therapy to support hematological recovery in the adverse setting of acute GvHD in one patient 
in 2004, and later in a multi-center phase II clinical trial including 55 patients, reported in 
2008 (192, 193). After the preliminary success of MSC therapy with GvHD, MSC therapy 
was trialed in other inflammatory diseases and autoimmune diseases e.g. Crohn’s disease 
(194), arthritis (195) and lupus (196). However today, clinical trials also exist delivering 
MSCs as a regenerative therapy in the context of fibrosis and ischemia as seen in ischemic 
heart disease, liver cirrhosis, lung disease and AS (112, 197). 
  
Although originally engraftment and proliferation of MSCs was the desirable and expected 
effect, more recent studies suggest that MSCs are cleared within 24 hours of intravenous (IV) 
infusion (198-201). Yet despite brief survival of MSCs in the circulation, their therapeutic 
effectiveness remains and they are able to modulate the host’s immune response (193, 202). 
As a consequence, it is very important to determine the mode of action (MOA) of MSC 
therapy following IV infusion and by extension understand the relationship between MOA 
and delivery route.  
 
1.6.3.1 DELIVERY AND SAFETY   
 
MSCs have been administered by several delivery routes including local delivery by topical 
application or direct-tissue injection. The most common delivery route is IV infusion(203). 
Depending on the delivery route cells may have different MOAs, affected by their own 
viability, direct cell-contact or secretome, but equally by their interactions with blood, 
biomaterials and the surrounding milieu, including oxygen content. In this section I will focus 
on systemic infusion in line with our research on BM MSCs. 
 
In patients, a few hours after MSC IV infusion, the majority of cells are cleared from 
circulation, with few or none detected after 24h hours (201). Infused cells have been reported 
to accumulate in the lung, with a portion also moving to the spleen and liver (198-201). An 
anti-inflammatory/ tolerogenic response prevails after MSCs have been cleared, an effect 
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suggested to be due to MSCs’ ability to interact with the innate immune compartment of 
peripheral blood. Several mechanisms have been proposed based on in vitro human and in 
vivo rodent models, suggesting direct and indirect MOAs. De Witte et al. have demonstrated 
MSCs are phagocytosed by monocytes, skewing them towards an anti-inflammatory 
phenotype (203). Indirectly, MSCs may immunomodulate through the release of paracrine 
factors within eVs or by the fusion of MSC microparticles with the cell membrane of pro-
inflammatory CD14+CD16+ monocytes, inducing selective apoptosis (204). Even if MSC 
are cleared by the innate immune response, it is still important that they are viable upon 
infusion in order to exert a therapeutic effect, with heat inactivated cells not eliciting the same 
response (205). Complement recognition through C3c and C5 binding to the MSC surface, 
may increase phagocytosis, as well, as the viability of the MSCs post-infusion (33). 
  
A concern with systemic delivery has been blood compatibility with the possible risk of 
thrombosis and emboli occurrence (206). IV delivery targets the complement activation/ 
coagulation cascade, adding to the MSCs propensity for clot formation. These responses have 
previously been referred to as IBMIR (207). Another factor affecting coagulation has been 
TF/CD142, which, depending on the in vitro culture conditions of MSCs (number of passages 
and culture components) varies (154, 208, 209). BM MSCs at a low passage, with limited in 
vitro expansion, trigger only weak IBMIR whereas long-term expansion, exposure to 
activated lymphocytes in vitro, cryo-storage and freeze-thawing increase pro-thrombotic 
properties and TF expression. These differences also translate to clinical effects with 
increased blood activation markers. However, the hyperfibrinolysis marker D-dimer is not 
seen upon infusion (154). Nevertheless, comparatively to other MSC sources including 
placenta derived decidua and fetal membrane cells, BM MSCs trigger only minimal clotting 
(154, 210-212). 
  
MSC transformation caused by ex vivo expansion should also be considered a safety concern. 
This concern was originally linked to the hypothesis of engraftment and ectopic tissue 
formation following MSC transplantation. Several recent studies have demonstrated and 
discussed that the risk of such pathological transformation is low (213, 214). Nevertheless, 
for each MSC source and cell product, the risk needs to be determined. Current approaches 
determine a cell product’s genetic stability by DNA sequencing and karyotyping or assessing 
tumorigenicity through telomerase activity and soft agar tumor formation assays (214, 215). 
Further safety concerns include increased susceptibility to infection due to MSC 
immunosuppressive effects, and the acute and chronic immunogenicity of the MSCs (213, 
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216). In a recent systematic review looking into MSC IV therapy outcome, these two 
concerns were shown not to be significantly higher in patients treated with MSCs compared 
to control groups (216). 
 
1.6.3.2 CELL THERAPY CHARACTERIZATION GUIDELINES 
 
In the context of cell therapies, the ISCT has outlined guidelines for cell characterization, 
stressing the importance of potency testing as a measurement of: product quality, efficacy, 
consistency in eliciting a specific clinical response, appropriate dosing and stability e.g. shelf-
life and interactions with other products (217). To quantitatively assess the potency of a cell 
product, the “active substance” and the MOA need to be defined beyond physiological/ 
chemical parameters like cell surface marker expression, taking into consideration the clinical 
condition it should alleviate. In MSCs where MOA is foremost manipulation of the immune 
response, the ISCT has proposed that the in vitro IFNγ + TNFα MSC-licensing model can be 
used to quantify immunomodulatory potential. Furthermore, they encourage measuring IDO 
secretion following pro-inflammatory licensing and characterization of specific leukocyte-
MSC interactions depending on the cell therapy application (218). 
 
According to the European Medical Agency, MSCs therapies are classified as advanced 
therapy medicinal products (ATMP), a class of live pharmaceutical therapies including cell, 
gene and tissue products. New legal frameworks put in place at an EU level, and enforced 
through national regulatory agencies, ensure that ATMPs are tested for quality, safety and 
efficacy before reaching patients (218-220). Cell therapies must be produced according to 
good manufacturing practice (215). 
  
More specific guidelines exist based on the cell therapy product identity, its clinical 
application and MOA. To do this biological characterization justice, the product needs to be 
tested pre-clinically in vitro, and where of relevance, in vivo, with a series of “proof-of-
concept” functional assays (217). Although in vivo animal models remain to be used for bio-
distribution and toxicity studies, the EU regulation on ATMPs “Guideline on quality, non-
clinical and clinical requirements for investigational advanced therapy medicinal products in 
clinical trials” note that non-clinical models should be performed with the most 
pharmacologically relevant in vitro or in vivo models (221). When animal models are needed, 
a similar pathophysiology as seen in patients is preferable and the 3Rs (reduction, 
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replacement, refinement) principles should be considered, avoiding animal testing when it 
results in inconclusive data (221). Specifically, for immunomodulation studies, animal 
models can be difficult as a functioning host immune system is needed for the therapeutic 
effect and considerable differences are seen in human and rodent immune responses e.g 
human MSCs secrete IDO for immunomodulation, while murine MSCs produce nitric oxide 
(142). Under these circumstances, in vitro and ex vivo cell and tissue based models and in 
silico analyses are encouraged (221).  
 
1.6.4 ENDOMETRIAL CELL THERAPY  
 
For combating AS and atrophic endometrium, a hand full of cell therapies have reached 
clinical trials comprising menstrual blood	derived stromal cells (menSCs), umbilical cord 
(UC)	derived MSCs, bone marrow-derived mononuclear cells (BMMNCs) and a peripheral 
blood-derived mobilized mixed population (Figure 5) (125-127, 222, 223). For the most part, 
these therapies can be categorized as either angiogenesis-promoting cell therapies or stromal 
cell therapies (112). Although the intended MOA for these therapies differs, their common 
aim is to induce endometrial regeneration (a more detailed review can be seen in Queckbörner 
et al. (112)). 
  
In angiogenesis-promoting therapies, a heterogeneous population of hematopoietic cells is 
isolated from peripheral blood or BMMNCs and enriched for cells expressing the endothelial 
progenitor cell markers (CD133+) (125). Previously, it was hypothesized that BMMNCs may 
transdifferentiate into endothelial cells and engraft at the site of injection thereby ensuring 
angiogenesis, however substantial evidence suggests that this isn’t their MOA, with multiple 
animal models showing no engraftment or trans-differentiation following intra-muscular or 
systemic injection (224). BMMNCs may modulate their paracrine environment by secretion 
of growth factors (225), however a new study shows that inactivated BMMNCs also induce 
an anti-inflammatory response (224). Thus, it is likely that cells do not act exclusively via 
their secretome but rather trigger a local immune response which activates the wound healing 
cascade. Mechanism aside, CD133+ BMMNC therapy has shown a promising, if temporary 
effect with increased angiogenesis at three and six months post-treatment through an increase 
in the number of mature blood vessels (CD31+/alpha-smooth muscle actin+), increased 
endometrial thickness, resumed menstruation and a reduction in adhesions. At 19 months 
post-treatment five live births were reported in a study of 18 patients (125). 
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Clinical trials in endometrial regeneration involving stromal cell therapies are at an early 
stage. Autologous menSCs were isolated and in vitro expanded from the menstruate (CD 28 - CD 4) of seven AS patients, and then topically delivered to the uterine cavity following 
endometrial scratching (126). Clinical trial participants showed increased endometrial 
thickness and three pregnancies were achieved after one or more rounds of therapy in the 
cohort. However, given that severe AS patients frequently suffer from amenorrhea, it is 
questionable whether a sufficient amount of menstruate could be collected and expanded 
from these patients. Likewise, as the specific pathology of AS remains unclear, in particular 
how the eSCs are deregulated in this condition, it might be controversial to reintroduce the 
same pathological cells back to the uterus exacerbating the already inflamed state. An 
example of this might be endometriosis, where we see pathological migration and 
proliferation of stromal cells outside the uterus potentially caused by retrograde menstruation 
(226). 
 
In another clinical trial 25 AS patients were treated with UC MSCs within a biodegradable 
scaffold (127). Here, the patients also showed increased endometrial thickness following 
treatment and fewer adhesions, with 10 patients becoming pregnant within the follow-up 
period. Much like with the angiogenesis promoting therapies, these pilot clinical trials have 
not specifically investigated MOA and safety. In the past, stromal cell engraftment was 
assumed, with more recent studies suggesting that this mechanism is unlikely with most 
stromal cell therapies acting via their secretome and contact-mediated immunomodulation of 
their environment (227). Thus, it is no surprise that in Cao et al. no engraftment of UC MSCs 
was observed in the endometrium after treatment (127). Furthermore, it is difficult to 
distinguish between the effect of the biodegradable scaffold and the cells on endometrial 
regeneration. 
 
Understanding the MOA of a particular cell therapy, will likely determine what the most 
efficient delivery route will be i.e. IV, trans-myometrial injection or cell infusion directly into 
the uterine cavity. Likewise, delivery methods including scratching, biomaterials/ scaffolds 
and combination therapies (angiogenesis-promoting therapies combined with stromal 
therapies) should also be evaluated once the MOA has been identified (228). Currently all of 
the existing phase I endometrial cell therapy trials have understandably included very small 
patient cohorts and no vehicle control groups. However, the heterogeneous patient cohorts, 
poorly defined cell populations, different intervals of cell therapy regimes and varying 
follow-up periods make it difficult to compare between the studies. Nevertheless, as the 
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endometrial cell therapy pilots suggest promising preliminary results, further studies are 
underway, with more specific cell product characterization in line with the ATMP guidelines 
(112). Likewise, there is a need for further pre-clinical in vitro studies of stromal-immune 
cell interactions to determine the precise MOA. From a safety perspective, none of the above 
studies have addressed the incidence of fetal growth restriction and placenta accreta seen in 
AS patients (229, 230). Likewise, the thrombotic properties of endometrium derived stromal 
cells should be considered, as previous research on decidual stromal cells has demonstrated 
enhanced triggering of the coagulation cascade as a consequence of systemic administration 
(210).  
 
Figure 5: Endometrial cell therapies and current treatments for Asherman’s 
syndrome  
Schematic diagram of Asherman's syndrome and the current cell therapies being developed to treat it as well 
as existing therapies. Abbreviations: BMMNCs, bone marrow-derived mononuclear cells; UC-MSCs, 
umbilical cord mesenchymal stromal cells; menSCs, menstrual blood-derived stromal cells, PRP platelet rich 
plasma, IUD, intrauterine device. Diagram made using art from Servier Medical Art, licensed under a 
Creative Common Attribution 4.0 Generic.  
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2 AIMS 
 
The aim of this thesis is to investigate the biological and molecular mechanisms of 
endometrial regeneration during the proliferative phase of the menstrual cycle. I have sought 




Study I: Determine the transcriptional profile of PRM associated endometrial 
changes following mifepristone treatment. 
Study II: Characterize the phenotype of eSCs and their immunomodulatory capacity 
in vitro. 
Study III: Deconvolute the different stromal cell types, states and niches within the 
endometrium using single cell RNA sequencing. 
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3 MATERIALS AND METHODS 
All projects included in this thesis were approved by the Ethical Review Board in Stockholm 
(DNR: 02-410, 2015/367-31/4 ,2016/1582-3, 2018/1187-32).  
Detailed descriptions of laboratory techniques applied in this PhD project can be found in 
study I-IV manuscripts. Therefore, only the key methods and considerations are included 
below.  
3.1 MATERIALS 
3.1.1 ISOLATION OF HUMAN ENDOMETRIAL STROMAL CELLS, 
EXPANSION AND CHARACTERIZATION 
 
For studies II and III endometrial samples were obtained during the proliferative phase of 
the menstrual cycle. We chose this time point because the stromal cells are involved in 
endometrial repair and regeneration. The donor’s endometrial proliferative phase (CD 7–9) 
was calculated based on their previous time of menstruation, and biopsies were obtained from 
the functional layer of the endometrium using a pipelle aspirator.  
Samples were washed with phosphate-buffered saline (PBS) and minced into 2mm2 pieces. 
Depending on the study, a xeno-free (study II) isolation or gentle isolation (detailed below; 
study III) was performed. In study II we establish a xeno-free protocol for future pre-clinical 
cell therapy development, as some clinical studies have reported higher risk of fever related 
acute infusional toxicity with xenogenic material (216). In study III a gentle isolation was 
required as enzymatic tissue dissociation can alter the transcriptome and lead to unwanted 
cell death; factors heavily discussed in the application of single cell RNA sequencing (231). 
In study II endometrial tissue was enzymatically digested in complete media containing 
Minimum Essential Medium α (MEM α) with 5% pooled human platelet-lysate and heparin 
(20 µl/ml heparin 1000 IE/ml) using dispase II (0.75U/ml) for 45 min at 37°C and 5% CO2. 
This was followed by a further digestion with 1X TrypLE ™ Express Enzyme for 10 minutes 
at room temperature. In study III minced tissue was digested in complete media containing 
Dulbecco’s Modified Eagle’s Medium (DMEM) F12 and 10% fetal bovine serum using 
dispase II (0.5 U/ml) at 4°C overnight. The following day the tissue was digested further with 
collagenase III (150U/ml) and DNase (139U/ml). Isolated cells were treated with red blood 
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cell lysis buffer to remove all red blood cells from the cell suspension. Red blood cells are 
abundant in the endometrium but do not contain RNA so they cannot be sequenced.  
In study II cells were checked for the colony-forming unit-fibroblast (CFU-F) potential by 
growing cells at low seeding density in complete media for 14 days. This is a functional assay 
developed for MSCs to determine their abundance in vitro (232). MSCs can self-renew even 
at low seeding density while fibroblasts do not grow well under these conditions. Colonies 
of more than 32 cells were counted, allowing exclusion of cell types with fewer cell divisions 
e.g. transit amplifying cells.  
To further classify the eSCs in study II, we determined their cell-surface expression of MSC 
markers by flow cytometry (62). Flow cytometry is a technique that allows you to sort and 
functionally analyze (e.g. viability, proliferation index) cell populations based on their 
florescence. Cells are stained with fluorophore-conjugated antibodies and passed through a 
laser beam where the emitted light is characteristic of a particular fluorophore and by 
extension the antigen expressed on the cell surface. Using multi-color panels with different 
antibodies makes it possible to distinguish between cell subpopulations and quantify their 
abundance relative to each other. Serial monolayer expansion of eSCs on plastic will 
generally remove any epithelial, endothelial and residual hematopoietic cells as the 
environment is not favorable to their propagation. These cells require other growth factors, a 
feeder layer/ basement membrane substitute and specific media(84). To validate our cell 
population purity and MSC phenotype, eSCs were expanded until P3-4 the passage range 
applied in a clinical setting(193), detached from flasks and stained with the following 
antibodies based on the ISCT panel: CD73, CD90, CD105, CD14, CD19, CD34, CD45 and 
HLA class II.  We also stained with live/dead marker to ensure we were only evaluating live 
cells as viability will affect specificity of antibody binding and autofluorescence. Similarly, 
we included IgG controls for every fluorophore to identify unspecific-antibody binding. 
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3.1.2 ISOLATION OF HUMAN BONE MARROW DERIVED 
MESENCHYMAL STROMAL CELLS, EXPANSION AND 
CHARACTERIZATION 
 
In study IV BM MSCs were isolated, expanded and characterized as previously described 
(154). BM mononuclear cells were separated over a Percoll gradient and expanded in 5% 
human platelet lysate and heparin (20 µl/ml heparin 1000 IE/ml). All in vitro experiments 
with BM MSCs used cells at low passage (P2-4) which corresponded to the passages used in 
clinical projects(193). Additionally, cells were freeze-thawed directly before use on the day 
of experiments to mimic the clinical setting. Both cryopreservation and passage number are 
known to affect MSC functionality and immunomodulation thus we wanted to control for 
these variables to ensure our data was clinically relevant (233, 234). Cells were washed after 
thawing to remove residual dimethyl sulfoxide which has previously been linked to infusion-
related toxicity in patients(235).  
 
3.1.3 PREPARATION OF PERIPHERAL BLOOD MONONUCLEAR 
CELLS AND PLASMA FROM WHOLE BLOOD 
 
In studies II and IV blood products were used in different co-culture conditions. PBMCs 
were isolated from buffy coats as previously described (236, 237). For plasma and whole 
blood experiments in study IV, peripheral blood was drawn from healthy donors using non-
heparinized blood tubes without a vacuum to limit cell activation. Lepirudin was added to 
the blood instead of heparin to prevent coagulation, additionally it does not affect the 
complement system (238). Heat inactivation (HI) of the plasma causes protein aggregation 
and inhibits complement. For the isolation of plasma, the blood was kept on ice until 





3.2.1 DIFFERENTIATION ASSAYS 
 
As part of study II eSC characterization, mesodermal lineage differentiation potential was 
assessed. eSCs were evaluated for their ability to differentiate into adipocytes and osteoblasts. 
This is another requirement for MSC identity in vitro (62). However, it must be said that in 
vitro induced differentiation capacity does not directly correlate to in vivo multipotency 
(239). Osteogenic differentiation was determined by Alizarin Red staining of calcium 
deposits while Oil Red O was used to stain lipids produced by adipocytes. Osteogenic 
differentiation can only be achieved with an initially high seeding density and a confluency 
above 80% (240).  
 
3.2.2 SOFT-AGAR TUMORIGENICITY ASSAY 
 
An important consideration in ATMP development is patient safety. In study II several 
experiments were designed to assess ectopic tissue formation, the soft-agar tumorigenicity 
assay is an example. One property of transformed cells is anchorage independent growth, 
which frequently correlates with in vivo tumorigenicity (241). eSCs and Ishikawa cells were 
cultured in semi-solid agar using the CytoSelect 96-Well Cell Transformation Assay. The 
Ishikawa cells constituted a positive control as an endometrial adenocarcinoma cell line. At 
termination the 3D cultures were lysed, stained with calcein (a florescent dye) and using a 
plate reader the cell solution optical density was measured. By making a standard curve of 
known cell densities, the relationship between optical density and culture confluency could 
be determined. We measured initial and terminal optical density for all the donors to 
determine growth within 10 days. Culture confluency was an indicator of anchorage 
independent growth. If optical density readings decreased after culturing this indicated cell 
death. 
 
3.2.3 PRO-INFLAMMATORY CYTOKINE LICENSING 
 
As part of updated ISCT guidelines for MSC characterization, a strong focus is on their 
immunomodulation (242).  In study II, the in vitro licensing model with IFNγ and TNFα 
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imitated a pro-inflammatory milieu and provided us with information on how eSCs might 
respond to it. Conditioned media was collected and analyzed using enzyme-linked 
immunosorbent assays (ELISAs) for human IL6 and PGE2. IDO activity was determined by 
measurement of L-kynurenine concentration, which is a breakdown product of tryptophan. 
IDO and PGE2 have been identified as soluble factors modulating T cells (143, 165). IL6 is 
an important mediator in skewing monocytes to macrophage differentiation(179). 
Additionally, licensed eSCs were stained for the following markers for subsequent flow 
cytometry analysis: CD119 (IFNγ receptor), CD120a (TNFa receptor I), CD120b (TNFa 
receptor II), HLA class I and II. Changes in cell surface expression of these markers were 
indicative of the cell’s recognition and response to the licensing. In MSCs both HLA I and 
HLA II are upregulated by IFNγ and TNFα licensing (243). 
 
3.2.4 PERIPHERAL BLOOD MONONUCLEAR CELLS CO-CULTURE 
WITH ENDOMETRIAL STROMAL CELLS 
 
PBMC in vitro co-culture models provide us with information on how MSCs might directly 
or indirectly regulate immune cells. These assays are a further component recommended by 
the ISCT for stromal cell characterization and thus have been applied for eSCs in study II 
(218). PBMCs were labelled with CellTrace CFSE Cell Proliferation Kit to determine the 
effect of eSCs on their proliferation. Depending on the number of proliferations the 
fluorescent signal is reduced, each generation of cells represents a different peak on the flow 
cytometry histogram. PBMCs were activated with anti-CD2, anti-CD3 and anti-CD28 beads 
to mimic a pro-inflammatory environment and determine how eSCs may modulate them. 
eSCs and the activated PBMCs were co-cultured in contact and in transwell (0.4 µm 
membrane) for five days to identify how eSCs mediate immune cells by direct cell membrane 
contact or by the diffusion of secretory factors. The PBMCs were stained with antibodies 
suited to characterize CD4+T cell activation and differentiation. The following cell surface 
markers were stained for and checked by flow cytometry: CD3, CD4, CD25, CD27, CD127 
and CD45RA.  
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3.2.5 PERIPHERAL BLOOD MONONUCLEAR CELLS CO-CULTURE 
WITH MESENCHYMAL STROMAL CELLS PRE-EXPOSED TO 
PLASMA 
 
In study IV the PBMC co-culture model described above was optimized to account for the 
effect of blood BM MSC contact and how this modulates monocyte interactions. These 
assays are examples of pre-clinical in vitro assays to determine MOA with a specific delivery 
route, namely IV infusion in line with the ATMP guidelines for more specific pre-clinical in 
vitro studies (221). 
 
 BM MSCs +/- pre-exposure to plasma were cultured with PBMCs and monocyte subsets 
(CD14+) isolated using the Pan Monocyte Isolation Kit. The purity was evaluated using flow 
cytometry (92-93% CD14+), it was important to have a pure monocyte population so their 
specific modulation could be evaluated and distinguished from the general PBMC effect. The 
PBMC secretome was assessed using ELISAs against TNFa a pro-inflammatory cytokine 
and IL10 an anti-inflammatory cytokine to determine the effect of the MSCs on the 
inflammatory milieu. Monocyte migration towards the BM MSC secretome was evaluated 
using Boyden chambers. For this, CD14+ monocytes were loaded onto 3 µm pore sized 
polyethylene terephthalate membrane plate inserts. BM MSC +/- pre-exposure to plasma 
conditioned media was added to the bottom chamber of the Boyden chamber. Monocytes 
were co-cultured with the conditioned media for 3 h at 37 °C / 5% CO2. Media was 
subsequently removed from the bottom of the chamber and migrated CD14+ cells were 
counted, their viability was assessed and they were screened for chemotactic factors 
including MCP-1.  
 
Following the different co-culture conditions PBMCs were stained for monocyte and 
macrophage markers and checked by flow cytometry to determine the effect of the BM MSCs 
+/- pre-exposure to plasma on the skewing of the monocyte phenotype and their macrophage 
differentiation: CD206, CD163, CD14, CD16 and HLA class II. 
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3.2.6 MICROARRAY  
 
A microarray is a chip with a collection of DNA probes, during an experiment sample RNA 
is hybridized to the chip and the signal collected from the probe provides an estimation of 
the gene expression in the sample. Microarray data provides comprehensive large scale gene 
expression profiles (14,500 well-characterized human genes) making it possible to identify 
dysregulated molecules and signaling pathways in a biological sample (244). In study I RNA 
from PAEC and non-PAEC samples was reverse transcribed to cDNA, further transcribed to 
labeled cRNA and hybridized to GeneChip® Human Transcriptome Array 2.0 ST. The raw 
data files of HTA 2.0 were processed using Affymetrix® Expression Console Software and 
expression data for all the samples were obtained with the following parameters: iterative 
Probe Logarithmic Intensity Error Estimation (iterPLIER) as the summarization algorithm 
with perfect-match GC composition-based background correction. Quantile sketch 
normalization was applied, and the probe sets that were not annotated were discarded from 
further analysis.  
 
3.2.7 SINGLE CELL RNA SEQUENCING 
 
Single cell RNA sequencing (scRNA-seq) is a relatively new approach to sequencing 
technology and provides vast knowledge on a single cell’s transcriptome in a specific sample 
at a given timepoint. Changes in gene expression between individual cells allows biological 
differences to be inferred relating to cell function, activation state and differentiation 
trajectory. It is also used to reveal information regarding previously unknown cell types 
(245).  
 
In study III freshly isolated, unsorted endometrial single cell suspensions were prepared and 
loaded on a 10x Genomics Chromium Controller instrument for single-cell gel bead-in-
emulsion (GEM) formation and barcoding. The advantage of the GEM technique is that 
individual cells can be captured without elaborate sorting and multiple assay plates. GEM 
reverse transcription was performed. Once cDNA was generated, amplified by PCR and 
cleaned, the sequencing libraries were constructed. Three runs of scRNA-seq were performed 
as patient samples were collected and processed on different days according with the clinical 
schedule and donor availability. Each run consisted of one sample/sequencing lane with 
approximately 3,000 cells sequenced per sample with a sequencing depth of 50,000 reads per 
 42 
sample. These parameters were considered appropriate for identification of stromal subsets 
within a mixed cell population. scRNA-seq output files were aligned to the human genome 
version 19 transcriptome using STAR mapper (246). Cell Ranger was used to process raw 
sequencing data.  
 
The downstream analysis of filtered cells was primarily performed in R using the Seurat suite 
(247, 248). Quality control measures were performed to remove doublets and dying cells as 
their altered transcriptome would confound scRNA-seq results. Only cells expressing 
between 200 – 5,000 genes, and less than 10% of mitochondrial genes were kept. RNAs 
coding for mitochondrially localized proteins are upregulated in broken cells indicating loss 
of cytoplasmic content (249). All cells were normalized according to their cell cycle stage to 
ensure there was no expression bias relating to cell cycle effect within a cell type, this can 
overshadow differences between cell types (250). The data was corrected for batch effect 
using the integration tool sctransform, this ensured that differences in gene expression were 
not dominated by inter patient heterogeneity (251). The dimensionality of the data was 
reduced using principal components analysis (PCA). Elbow plot was used to select top 
principal components which were used for downstream Louvain clustering and visualization 
using t-distributed stochastic neighborhood embedding (tSNE) and uniform manifold 
approximation and projection (UMAP). “Reference-Based Single-Cell RNA-Seq Annotation 
tool SingleR was run to broadly identify cell types based on machine learning using the 
reference dataset “Human Primary Cell Atlas”  (252). Final cell type labels were established 
after manual assessment using known marker genes. Velocyto was used to evaluate cell 
lineage by cell dynamics and RNA velocity, this is based on splicing information (253).  
 
The main differences between the high throughput genomics techniques used in study I and 
study III are that whole endometrial tissue was homogenized before RNA extraction in 
study I providing pooled transcriptional information while in study III gene expression is 
captured for each individual cell. Both approaches can provide a transcriptional profile for 
endometrium, however the single cell approach is sensitive to differences between cell types. 
In a complex tissue with multiple cell types and functions, homogenized sections may 
disproportionally represent a certain cell type (12).  
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2.3 STATISTICAL ANALYSIS 
 
In study I, the microarray data were tested for any interfering outliers, and quality control 
was assessed with MA plots which visualized any differences between the two channels (dye 
coupling and hybridization efficiencies). Hierarchical clusters grouped genes with similar 
expression patterns together and PCA provided principal gene components identifying genes 
that explain the experimental setting. For the downstream analysis, Significance Analysis of 
Microarrays (SAM) method was applied(254). Normalized data from microarray and real-
time PCR were subjected to unpaired two-tailed Student’s T test to find significance between 
groups. A p-value < 0.05 was considered significant.  
In study II comparisons in the groups were analyzed using one-way ANOVA with paired 
two-tailed T test. Mann Whitney U test or Wilcoxon test was used where data was non- 
parametric. Normality was determined by the Shapiro-Wilk test. Equal variance was 
determined by Bartlett’s Test and F Test when assuming Gaussian distribution. Statistical 
significance was assumed at p < 0.05). 
In study III Changes in scaled gene expression between cell types were calculated using the 
MAST test (255). MAST is an improvement over the generic non-parametric Wilcoxon text. 
MAST uses a generalized linear model framework that considers the bimodal nature of 
single-cell expression data due to stochastic drop-outs. MAST offers a differential gene 
expression test that is custom tailored for single-cell count data. A log fold change of 2 or 1.5 
and adjusted p-value of 0.05 was applied to determine highly unique genes in different 
subsets. The adjusted p-value/ false discover rate was based on Bonferroni correction using 
all genes in the dataset.  
 In study IV data were assessed for normality using the Shapiro-Wilk test, and equal 
variances using the F test. Parametric data were statistically evaluated using Student’s T test, 
with non-parametric data assessed using the Mann-Whitney test (where data was unpaired), 






Several benign gynecological disorders including HMB, endometriosis and AS show 
evidence of impaired inflammatory control, wound healing and endometrial proliferation. To 
understand these disorders better, greater understanding of healthy menstruation and 
regeneration of the endometrium is needed. These parallel processes are orchestrated by close 
interactions between hormonal regulation, immune cells and the stromal compartment. The 
following results address the different elements involved in controlling the endometrial 
proliferative phase. 
4.1 STUDY I 
 
Although PAEC is not considered a gynecological disorder, the endometrium has an “out of 
cycle” phenotype which may be at least partly due to unopposed E2 levels. PAEC presents 
temporarily in a number of women following continuous PRM usage. The altered 
morphology includes dilated cystic glands and compact non-decidualized stroma (103, 106). 
As PRMs including mifepristone may be developed for contraceptive use, and are already 
being applied as a treatment for benign gynecological disorders, it is important to further 
investigate these morphological changes (256). PAEC is a model of disrupted endometrial 
hormonal-homeostasis, providing insights into E2’s role in endometrial structural 
organization. Consequently, endometrial biopsies from women presenting with the PAEC 
phenotype after three months of mifepristone treatment were collected and the tissue’s 
transcriptional profile was assessed.  
 
 4.1.1 EFFECT OF PROGESTERONE WITHDRAWAL AND CONTINUED 
ESTROGEN SURGE ON THE STROMAL CELL TRANSCRIPTIONAL PROFILE  
 
The E2 surge activates endometrial repair following menses with gland led re-epithelization 
and stromal proliferation (257). In vitro and in vivo studies have demonstrated that E2 
regulates signaling between the epithelium and stroma, activating their simultaneous 
proliferation (59). In vitro stromal cell cultures treated with E2 and P4 show changes in ECM 
production demonstrating the important role of hormonal regulation in stromal compartment 
structural reorganization (258). This study provides specific transcriptional information on 
the effect of E2 surge and P4 withdrawal on the stromal compartment. 
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4.1.2 KEY FINDINGS 
 
v 68 genes were differentially regulated between the PAEC and the non-PAEC samples 
(fold change ≥2 and an FDR value ≤0.05) (see Table 2). 
v IPA analysis confirmed no pathways relating to cancer were significantly activated or 
inhibited with treatment. 
v Genes which showed an altered expression could be assigned largely to three functions: 




Table 2: Microarray analysis of genes differentially regulated with a fold 
change ≥2 and an FDR ≤0.05 in PAEC samples compared with non-PAEC) 
 
Gene Gene Name Fold 
Change 
CRABP2 cellular retinoic acid binding protein 2 3.4 
ASPM abnormal spindle microtubule assembly 3.2 
KNL1 kinetochore scaffold 1 3.1 
MKI67 marker of proliferation Ki-67 3 
DIAPH3 diaphanous related formin 3 2.9 
ANLN anillin actin binding protein 2.9 
S1PR3 sphingosine-1-phosphate receptor 3 2.8 
FBN2 fibrillin 2 2.8 
SFRP1 secreted frizzled related protein 1 2.8 
TPX2 TPX2, microtubule nucleation factor 2.8 
MELK maternal embryonic leucine zipper kinase 2.8 
TTK TTK protein kinase 2.8 
WIF1 WNT inhibitory factor 1 2.7 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 2.7 
PCDHB7 protocadherin beta 7 2.7 
THY1 Thy-1 cell surface antigen 2.7 
NUF2 NUF2, NDC80 kinetochore complex component 2.7 
HMCN1 hemicentin 1 2.6 
CENPU centromere protein U 2.6 
ADAMTS16 ADAM metallopeptidase with thrombospondin type 1 motif 16 2.6 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 2.5 
TNC tenascin C 2.5 
LOXL1 lysyl oxidase like 1 2.5 
KIF11 kinesin family member 11 2.5 
EDNRB endothelin receptor type B 2.5 
SNORD16 small nucleolar RNA, C/D box 16 2.4 
GBP3 guanylate binding protein 3 2.4 
VWF von Willebrand factor 2.4 
PRSS23 protease, serine 23 2.4 
BUB1 BUB1 mitotic checkpoint serine/threonine kinase 2.4 
CD248 CD248 molecule 2.4 
LOX lysyl oxidase 2.4 
PLAT plasminogen activator, tissue type 2.4 
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MAP1B microtubule associated protein 1B 2.4 
PBK PDZ binding kinase 2.3 
CD34 CD34 molecule 2.2 
BGN biglycan 2.2 
PDPN podoplanin 2.2 
SYT11 synaptotagmin 11 2.2 
FBLN5 fibulin 5 2.2 
TPTEP1 transmembrane phosphatase with tensin homology pseudogene 1 2.2 
IFI44 interferon induced protein 44 2.2 
MACC1 MACC1, MET transcriptional regulator 2.2 
FLRT2 fibronectin leucine rich transmembrane protein 2 2.2 
OAS2 2'-5'-oligoadenylate synthetase 2 2.2 
DTL denticleless E3 ubiquitin protein ligase homolog 2.1 
CENPK centromere protein K 2.1 
APOE apolipoprotein E 2.1 
PXDN peroxidasin 2.1 
EPSTI1 epithelial stromal interaction 1 2.1 
PRC1 protein regulator of cytokinesis 1 2.1 
KIRREL kin of IRRE like (Drosophila) 2.1 
TCEAL7 transcription elongation factor A like 7 2 
PAG1 phosphoprotein membrane anchor with glycosphingolipid 
microdomains 1 
2 
RNU5A-8P RNA, U5A small nuclear 8, pseudogene 2 
FAM43A family with sequence similarity 43 member A 2 
CDH5 cadherin 5 2 
CHN1 chimerin 1 2 
RAMP2 receptor activity modifying protein 2 2 
RNU5D-1 RNA, U5D small nuclear 1 2 
ITGA5 integrin subunit alpha 5 2 
ADAM12 ADAM metallopeptidase domain 12 2 
TRAM2 translocation associated membrane protein 2 2 
ST6GAL2 ST6 beta-galactoside alpha-2,6-sialyltransferase 2 2 
DHFR dihydrofolate reductase 2 
PCDHB11 protocadherin beta 11 2 
COPZ2 coatomer protein complex subunit zeta 2 2 






Based on the microarray analysis and its technical validation via qPCR we were able to see 
that differences in gene expression between PAEC and non-PAEC biopsies were largely 
associated with an altered ECM (ADAMTS16, FBN2, FBLN5, FLRT2 and ADAM12) and 
activity in the perivascular environment (THY1, EDNRB, VWF, CD34) within the stromal 
compartment. Between late secretory phase and early proliferative phase, changes in the 
interstitial ECM, basement membrane and vascular permeability are hormonally regulated to 
ensure controlled tissue breakdown and repair. Overall, temporary morphological changes 
seen in the histological assessments of the PAEC biopsies were accompanied with a 
transcriptional profile indicative of structural changes in the stroma. Study I introduced the 
diversity of stromal niches and how hormonal regulation affects structure and functionality. 
 
A limitation of this study was extracting RNA from whole endometrial tissue, this may bias 
a gene profile to the most abundant cell-type in the biopsy and might explain why we see 
such a strong stromal gene profile. Nevertheless, by enzymatically digesting the tissue and 
analyzing the cell types individually we might have altered the transcriptional profile of 
PAEC. 
 
4.2 STUDY II 
 
eSCs are being developed as an anti-inflammatory/ anti-fibrotic therapeutic to combat AS 
and RIF (112, 126, 127). Although these pilot studies are promising, a thorough 
characterization of the eSCs is needed, encompassing their phenotypic, immunomodulatory 
properties and safety testing e.g. tumorigenicity (62, 214, 218, 242). We sought to investigate 
in vitro expanded, proliferative phase eSCs in line with the ISCT guidelines for minimal 
characterization of MSCs, their response to a pro-inflammatory licensing and their effect on 
CD4+ T cell differentiation and proliferation. Through karyotyping, telomerase related 
assays and soft-agar cultures expanded eSCs chromosomal stability and tumorigenicity was 
assessed. 
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4.2.1 PROLIFERATIVE PHASE ENDOMETRIAL STROMAL CELLS PRESENT 
UNIQUE IMMUNOMODULATORY ADAPTATIONS 
 
Surprisingly little is known about the functionality of the proliferative phase eSCs and their 
response to cytokines and modulation of leukocytes in the context of regeneration. Previous 
research into the regenerative properties of the endometrium have frequently limited 
themselves to the perivascular environment with a strong focus on the role of the ESPs 
(CD146+ PDGFRβ+) in controlling regeneration rather than addressing the larger stromal 
tissue’s cellular heterogeneity (9, 61, 67). Likewise, immunological assessments of the 
endometrium have focused on the window of implantation or the decidua following 
placentation (12, 20, 48, 259). 
  
The stromal compartment in the endometrium undergoes major structural changes during 
menstruation and regeneration, taking cues from inflammatory mediators (cytokines, 
chemokines and prostaglandins) and leukocytes (20). In the context of cell therapy, previous 
clinical trials applying external stromal sources e.g. UC MSCs to regenerate the endometrium 
do not address the unique immune-privileged site that is the uterus, assuming MSC sources 
are interchangeable (222).  Consequently, it is important to determine the immunomodulatory 
potential of eSCs and their similarity to other MSC sources. At the same time our findings 
should improve our understandings of healing and regeneration following menstruation. 
 
4.2.2 KEY FINDINGS 
 
v eSCs can be reliably isolated and expanded, form colonies at low seeding density and 
show no significant differences in growth kinetics within the first four passages 
(determined as the number of passages required to generate a therapeutic dose for 
clinical applications) or between donors. 
v eSCs express cell surface markers in line with ISCT MSC guidelines; positive for 
CD90, CD73, CD105, and HLA class I (> 95%) and were negative for CD45, CD34, 
CD19, CD14, and HLA class II (>2%). 
v eSCs are genetically stable following in vitro expansion,  with low telomerase activity, 
no karytotypic changes, and low anchorage independent growth (tumorigenic potential). 
v  eSCs license to an anti-inflammatory phenotype without upregulation of HLA class II. 
 50 
v eSCs modulate the proliferation, activation, and differentiation status of CD4+ T cells, 
skewing them toward an EM phenotype.  
v eSCs prove to be more effective, in vitro, in their immunomodulation via their 
secretome (see Figure 6 for summary of eSC immunomodulation). 
 
Figure 6: Endometrial stromal cell immunomodulation 
Schematic diagram of endometrial stromal cells and their putative modulation of immune cells based on our 
pro-inflammatory licensing and activated PBMC co-culture experiments. Abbreviations: (NK) natural killer, 




As the number of MSC therapies from different stromal sources is steadily expanding, 
regulatory requirements for cell characterization and MOA are adjusting, revealing unique 
cell properties indicative of a cell source’s in vivo niche. This certainly applies to expanded 
eSCs which express the phenotypic hallmarks of MSCs, however their lack of cell surface 
expression of HLA class II in a licensed/ pro-inflammatory environment suggest they have a 
unique immunomodulatory phenotype. This distinguishes them from other MSC sources e.g. 
bone marrow, adipose and fetal stromal tissue(237, 260, 261).  
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No chromosomal abnormalities were observed in the in vitro expanded eSCs, they showed 
no anchorage independent growth and telomerase activity was low. This confirms previous 
MSC studies which indicate no evidence of genomic instability or tumorigenicity in 
expanded human stromal cells (262-265). MSCs uphold tissue homeostasis by regulating 
inflammation and repair through their secretome (266), consequently it is important to 
understand how stromal cells interact with the innate and adaptive immune system. Pro-
inflammatory cytokine (IFNγ and TNFα) licensing experiments upregulated IDO, IL6, and 
PGE2 in eSC spent media indicating a switch to an immunomodulatory/suppressive profile. 
Perhaps, indicative of T, NK and dendritic cell suppression (165, 180, 267). PGE2 has been 
reported to promote proliferation of epithelial cells and contribute to angiogenesis suggesting 
its role in wound healing (236, 268). In line with MSCs, our findings show that eSCs suppress 
activated CD4+ T cell proliferation via cell-to-cell contact and paracrine factors when co-
cultured with PBMCs (162, 167, 269). eSCs primarily modulated the CD4+ memory T cell 
subsets, foremost increasing CD4+ T cell differentiation towards an EM T cell state. In 
decidualized endometrial stroma and first trimester decidua CD8+ T cells present an EM state 
as well (45, 52, 54). The general EM phenotype in the reproductive tract is in line with that 
seen in other mucosal linings, EM T cells are the first line of defense against reinfection 
(270).  
We conclude that the endometrial stromal compartment shares phenotypic characteristics 
with MSCs in terms of cell surface marker expression, ability to attach to plastic, and 
differentiation capacity. However, their regulation of HLA class II and memory T cell subsets 
suggests more tissue origin specific immunomodulation. At the same time this study 
demonstrated that MSC markers, colony forming properties and differentiation capacity is 
not unique to ESPs as eSCs representing the bulk of the endometrial stromal compartment 
also meet these requirements. This contributed to our curiosity to start study III and delineate 
the different populations in the stromal compartment, finding better criteria to distinguish 
between the subsets at a molecular level.  
 
4.3 STUDY III 
 
Understanding the cellular interactions between fibroblasts, progenitor cells and transit 
amplifying cells driving regeneration will provide us with a starting point to understand how 
these mechanisms are derailed in chronic inflammatory disorders e.g AS and HMB. Other 
stromal compartments in the lung and lymph node have eloquently shown to be composed of 
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different subsets indicative of niche, activation status and injury response (77, 78, 271). 
Consequently, we have applied single cell RNA sequencing to proliferative phase 
endometrium functionalis to delineate the complexity within the stromal compartment, and 
the perivascular environment, and thereby understand their interactions and combined 
contributions to endometrial proliferation. 
 
4.3.1 ENDOMETRIAL STROMAL CELLS ARE A HETEROGENOUS POPULATION 
OF CELLS WITH ADAPTATIONS FOR DIFFERENT NICHES AND ACTIVATION 
STAGES  
 
Our previous studies, and the wider literature demonstrate that eSCs respond to hormonal 
changes by altering the ECM composition and their rate of proliferation (258). Likewise 
changes in the inflammatory environment prime the cells to different activation states and 
trigger the release of inflammatory mediators which recruit and suppress leukocytes. 
Decidualization and the menstrual cascade originates in the perivascular environment where 
a set of stromal cells reside in a niche, taking cues from the vasculature (20). Given the 
knowledge of these different processes, and that menstruation and regeneration occur in 
parallel at different foci across the endometrium, we expected to see higher complexity in the 
stromal tissue with subsets of stromal cells undergoing different processes to mediate 
regeneration.  
 
 4.3.2 KEY FINDINGS 
 
v Multiple stromal environments exist within the endometrial functionalis with unique 
transcriptional profiles. 
v Six stromal subsets have been identified, several associated with an activated fibroblast 
phenotype e.g. ISG15+ cells, while others possibly regulate epithelial cells and uphold 
their stem cell niche e.g. BMP7+ cells or stromal cells contributing to the perivascular 
environment e.g. ACTA2+ and THY1+ cells(see Figure 7). 
v Within the perivascular cell fraction, transcriptional data suggest cells can be 
distinguished as mural cells and smooth muscle cells. 
v Current ESP markers are not specific on a transcriptional level and they cannot 
distinguish between smooth muscle cells, mural cells and ESP. The transcriptional 
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profile is more specific to perivascular location than cell type distinctions (see Figure 
8). 
v  A published single cell RNA sequencing dataset was used for external validation of 




Figure 7: Analysis and subtyping of the endometrial stromal cell compartment 
A. UMAP plot showing ten clusters of endometrial stromal cells and a cluster of perivascular cells on the far 
right. Clusters are labelled as per their identified expression profile in B. B. Dotplot showing the top 
differentially expressed genes (rows) for the ten stromal clusters (columns).  Genes were selected based on 
MAST test with a minimum log fold change of 2 and adjusted p-value of 0.05. Note that the color scale is 
clipped at 2.5. Stroma 1, 2 and 3 do not show any unique expression. The PAGE4+ cluster shows a very biased 
differential expression for PAGE4 only. The ECM, ACTA+ and BMP7+ clusters show a higher expression for 
genes involved in ECM breakdown, remodeling and organization. The CTNNB1+ cluster shows higher 
expression of genes involved in epithelial regulation and innate immunity. The ISG15+ cluster shows higher 
expression for genes involved in innate immunity. The THY1+ cluster shows higher expression of genes 
involved in Notch signaling. 
12
A) b)B)
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Figure 8: Analysis of cell subsets in the perivascular environment  
A. UMAP plot of endometrial stromal cells and perivascular cells highlighting cell subsets ACTA2+, THY1+ 
and pericyte 1 and 2 (in black). B. UMAP plot of endometrial stromal cells and pericytes showing increased 
expression of THY1 with increasing proximity to the pericyte cluster at the top right. C. UMAP plot showing 
groups ACTA2+, THY1+ and Pericyte 1 and 2. D. UMAP plot showing expression pattern of genes PDGFRB, 
MCAM, SUSD2 and THY1. None of these markers can exclusively identify any of the clusters mentioned in C. 
E. PCA scatterplot showing RNA velocity. Predicted developmental trajectory between clusters is displayed as 
a vector field. Short arrows indicate a steady state and long arrows indicate active progression towards a 
differentiated state. Cells differentiate along the direction of the arrow, here indicating some of the THY1+ cells 
committing towards the Pericyte1. F. Heatmap showing the top differentially expressed genes (rows) for each 








Our transcriptional data suggests there are multiple stromal cell profiles which may represent 
different cell types, states or niches. Six profiles clearly distinguished themselves in our 
analysis, of which three are retained throughout the menstrual cycle and into early pregnancy 
(external dataset).  These subsets may contribute to the tissue regeneration and warrant 
further protein validation and functional in vitro testing. Specific subsets suggest different 
activation states of stromal cells presumably involved in wound healing and modulation of 
leukocytes and cytokines. The ISG15+ population presented an interferon regulated gene 
profile, and based on literature and data from study II, this may present an activated stromal 
subset involved in tissue breakdown and repair (272). The CTNNB1+ population includes 
genes linked to M2 macrophage polarization (273-275). In vitro and in vivo studies have 
demonstrated that MSCs may contribute to macrophage polarization to a M2 pro-healing/ 
anti-inflammatory state via paracrine mechanisms (180, 276). The BMP7+ population has 
genes involved in myofibroblast differentiation, epithelial mesenchymal transition (EMT) 
and TGFβ1-Wnt signaling (PRSS23, ITGA8, BMP7, ITM2A and ARHGAP29) and also bear 
some resemblance with the intestinal mesenchyme niche, protecting and conserving the 
epithelial stem cells showing expression of CD34 and RSPO1 (86, 277-280). Furthermore, 
single cell RNA sequencing provides detailed transcriptional information about the 
perivascular environment, assumed to be the niche of ESPs (61, 67, 281). Although multiple 
cell types could be identified in this environment, current marker genes do not exclusively 
distinguish a stromal population from smooth muscle cells or mural cells in the perivascular 
space. It is not known whether the proteins corresponding to the mentioned marker genes are 
more discriminatory within the perivascular environment. Currently, perivascular cells 
(mural and smooth muscle cells) and ESPs are isolated and expanded using the same cell 
surface markers (71).Consequently, it is important to validate these findings to ensure marker 
specificity. Overall this study has provided descriptive data on the complexity of the stromal 
compartment and should act as a starting point to further investigate different stromal subsets 
on a protein and functional level to provide us with new knowledge to explain mechanisms 
controlling endometrial regeneration. 
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4.4. STUDY IV 
 
As investigated in study II, MSC and eSCs can mediate immune cell subsets via cell-
membrane mediated contact or their secretome in in vitro co-culture models. However, in the 
clinical setting MSC MOA after IV infusion is largely unknown, MSCs rarely reach the target 
site and are cleared from circulation rapidly (154). Nevertheless, this does not affect their 
efficacy and their ability to modulate the host immune system (193). When developing MSC 
cell therapies, MOA and potency are heavily affected by the intended delivery route. The aim 
of this study was to determine the effect of blood components on BM MSC viability and 
immunomodulation.  
 
4.4.1 BLOOD COMPONENTS PROMOTE IMMUNOMODULATION THAT 
PERSISTS WITHIN THE SYSTEM BEYOND INFUSED MESENCHYMAL 
STROMAL CELL CLEARANCE 
 
This study distinguishes itself from the other studies within this thesis, in its use of BM 
MSCs. However, the results are applicable to endometrial regeneration and the role of the 
stroma. In the context of endometrial cell therapy, it is important to address the delivery route 
early on as it will affect the MOA of the cell product, as well as their potency. MSCs have 
been said to trigger the instant blood mediated inflammatory response, thereby activating the 
complement and coagulation cascade. In the context of the endometrium, these actions are 
very important as we know they are both heavily involved in controlling menstruation and 
tissue repair (20). Additionally, placenta derived decidual stromal cells have shown a high 
expression of TF and thus clotting capacity, mechanisms that should be considered when 
designing a cell therapy and its application (154, 210).  
 
4.4.2 KEY FINDINGS 
 
v Exposure to blood plasma results in rapid lysis of BM MSCs with surviving BM MSCs 
showing reduced viability and cell swelling. 
v Plasma borne C3c fragments bind to the surface of BM MSCs in a time dependent 
manner, modulating their expression of complement receptors (C3aR and C5aR) but not 
complement inhibitors (CD46, CD55 and CD59). 
 58 
v BM MSCs exposed to plasma secrete reduced levels of MCP-1, resulting in the reduced 
recruitment of monocytes. 
v MSCs exposed to plasma and whole blood modulate the phenotype of CD14+ monocytes, 
resulting in a predominantly anti-inflammatory CD14+CD16- classical monocytic 
compartment, with downregulation of pro-inflammatory CD14loCD16+ non-classical 
monocytes. 
v The introduction of BM MSCs to whole blood increases plasma levels of IL6, modulating 







Figure 9: Following blood exposure survivor MSCs are phenotypically altered 
and affect maturation and functionality of innate immune cells 
1. BM MSCs are intravenously infused. 2. After exposure to blood BM MSCs’ cell membrane is compromised 
with further mitochondrial depolarization, cell swelling and lysis. This results in a spillage of cellular contents, 
including interleukin (IL)-6, membrane particles (MPs) and extracellular vesicles (eVs) into the plasma. 3. 
Survivor BM MSCs are subjected to complement fragments, with cell surface binding of C3c. The BM MSCs 
try to compensate with expression of the complement inhibitors CD46, CD55 and CD59 and by modulating 
their complement receptors, with downregulation of C3aR and upregulation of C5aR. 4. The innate immune 
system responds with elevated IL6 levels and 5. free MPs fuse with the monocyte cell membrane, skewing their 
distribution to a predominantly anti-inflammatory CD14+CD16- classical monocytic compartment 6. There is 
an increase in the frequency of both monocytic myeloid derived suppressor cells (Mo-MDSCs) and 
polymononuclear myeloid derived suppressor cells (PMN-MDSCs). 6. Anti-inflammatory cytokines such as 
IL10 and a downregulation in pro-inflammatory cytokines tumor necrosis factor alpha (TNFa) create an anti-
inflammatory milieu able to skew the adaptive T cells to a regulatory profile. 7. Remaining MSCs surviving 
their peripheral interactions are trafficked to the lungs, where they are cleared from the system. 
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4.4.3 DISCUSSION 
 
Based on our data and the literature, BM MSCs exposed to whole blood intravenously are 
lost. This process may be mediated through bioactive molecules such as complement 
fragments. In our results, this was exemplified by our active plasma experiments where C3c 
fragments bound to the cell surface of the BM MSCs and increased with time. These effects 
were not seen in the heat inactivated (HI) plasma experiments. Significant increases in the 
cell area of the BM MSCs were seen in both the active plasma and HI plasma treated samples, 
indicating early stage necrosis as the cell swells prior to rupture. Previous research has 
suggested that BM MSCs modulate the innate immune response by rupturing their cell 
membrane and spilling out their intracellular contents (186). These things considered, there 
may be several cascades and mediators which induce damaging effects upon contact with 
blood components. The ability of the BM MSCs to modulate the innate immune system 
despite cell death, suggests they release free factors, membrane particles and extracellular 
vesicles able to trigger immunomodulatory effects by themselves. Although the cell fate of 
BM MSCs appears to be cell death on delivery several studies have stressed the importance 
of viability at the point of administration. This may be because the cells need to be alive long 
enough to release stored immunomodulatory factors upon delivery or give them the 
opportunity to modulate their secretome towards an anti-inflammatory profile. However, it 
would also be interesting to see how heat inactivated BM MSCs might modulate the innate 
immune system without their soluble repertoire but only through cell membrane contact, this 
has been shown to be effective in other cell therapies when determining the mechanism of 
action (187, 224).  
 
General exposure to plasma demonstrated a decrease in the secretion of the monocyte 
recruitment chemokine, MCP-1, which led to a suppression in the directed recruitment of 
monocytes in culture. These data demonstrate that those cells surviving plasma contact, are 
able to significantly modulate their secretome within 24 hours. Furthermore, regardless of 
co-culture conditions (whole blood or plasma) BM MSCs significantly reduced the frequency 
of CD14+ monocytes, showing a particularly suppressive effect on the non-classical 
monocytes. BM MSCs increase the frequency of monocytic myeloid derived suppressor cells 
(Mo-MDSCs) and polymononuclear myeloid derived suppressor cells (PMN-MDSCs). Both 
subsets of these cells have immunosuppressive potential, with Mo-MDSCs secreting anti-
inflammatory factors such as IL10, TGFβ1 and IL6, which have positive feedback 
mechanisms on monocytes to further promote their skewing away from dendritic cell 
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differentiation and the pro-inflammatory non-classical monocyte phenotype, as well as in the 
promotion of regulatory T cells (146, 282, 283). 
 
 In conclusion, BM MSC contact with blood triggers an innate immune response, resulting 
in an anti-inflammatory skewing of the monocyte profile, with elevated levels of classical 
monocytes and an increase in the frequency of both Mo-MDSCs and PMN-MDSCs. This 
shift in the peripheral immune repertoire may provide the foundation for modulation of T and 
B cells, and induction of tolerogenic responses lasting longer than the BM MSCs themselves.
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5 CONCLUSION 
 
This thesis focuses on endometrial stromal regeneration, addressing the key regulatory 
elements including hormones, immune cells and stromal progenitor populations. All 
components need to be considered when understanding endometrial healing, its deregulation 
in benign gynecological disorders, and in novel cell therapy development for their alleviation. 
 
The transcriptional data in study I suggest that P4 withdrawal and unopposed E2 surge alter 
the endometrial structural organization and ECM composition particularly affecting the 
stromal compartment in the tissue. Morphological changes seen in PAEC do not suggest a 
pathological proliferative disorder with no genes identified associated with cancer 
progression.  
 
Study II provides a pre-clinical characterization of eSCs for future development of cell 
therapy. eSCs lack HLA class II cell surface expression and skew CD4+ T cell differentiation 
towards an EM phenotype. Thus, we have identified a unique immunomodulatory phenotype 
of eSCs making it clear that they should not be considered interchangeable with other MSCs.  
 
Study III addresses the different cell populations controlling endometrial regeneration, 
specifically delineating stromal subsets that might mediate tissue breakdown and repair. 
Several stromal subsets were identified suggesting different activation states, niches and 
functions. Furthermore, it addresses the perivascular niche and the controversy surrounding 
existing markers for ESPs. In other words, whether existing markers can distinguish between 
mural cells, smooth muscle cells and ESPs.  
 
Study IV demonstrates that BM MSCs undergo cell death once exposed to whole blood 
explaining the clinical observation of BM MSC clearance following IV infusion. 
Nevertheless, BM MSCs can still modulate the innate immune response through the release 
of soluble factors when their membrane is ruptured and these factors skew monocytes to an 
anti-inflammatory phenotype. These changes in the monocyte subsets and their modulation 





6 FUTURE DIRECTIONS 
 
In completing this thesis project on endometrial regeneration and cell therapy development 
multiple research directions have emerged.  
 
Based on the findings in studies II, and IV and the research group’s interest in endometrial 
cell therapy, it would be fascinating to investigate the effect of whole blood on eSCs and their 
activation of coagulation cascades. This would address the questions concerning ideal 
delivery route and safety for a potential stromal cell therapy. At the same time these 
experiments might provide us with new knowledge relating to menstruation, where stromal 
cells would be in contact with open wounds and ruptures in the vasculature. Furthermore, the 
unique immunomodulatory properties of eSCs in regulating HLA class II cell surface 
expression warrant further exploration. Our initial investigation of the CIITA gene and the 5 
promoter regions controlling its gene expression (responsible for HLA class II protein) 
suggested that the gene is responsive to pro-inflammatory licensing, yet a transcriptional 
adaptation prevents this from being expressed as HLA class II on the cell surface. 
Investigating these adaptations would be interesting, especially in the current wave of 
induced pluripotent stem cell and embryonic stem cell therapies with HLA I and HLA II 
knockouts (284, 285). Understanding translational inactivation and regulation at the 
epigenomic level would be valuable for cell therapies and transplant tolerance. By extension, 
we have investigated the effect of eSCs on CD4+ T cells but haven’t addressed CD8+ T cells. 
As CD8+ T cells have been shown to be more abundant in the secretory phase endometrium 
and placenta derived decidua it would be interesting to determine their differentiation state 
in the proliferative phase, as well as investigating the interaction between HLA class II and 
CD8+ T cells. 
 
The single cell RNA sequencing in study III warrants considerable validation. To 
appropriately confirm the diversity observed within the endometrial stromal compartment 
RNAScope is planned for technical validation of gene-profiles, as well as, to spatially locate 
specific niches in the tissue relative to epithelial, endothelial and perivascular cells. The gene 
profiles which can be validated using RNAScope will also be checked on a protein level 
using immunohistochemistry. Furthermore, additional bioinformatic analysis using 
CellPhone DB to determine the ligand-receptor interactions between different activated 
stromal subsets and immune cells would provide interesting data in the context of 
endometrial regeneration (286). To address the endometrial perivascular environment 
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queries, it would be possible to stain freshly isolated eSCs with all the existing ESP markers 
and apply fluorescence-activated cell sorting to these cells followed by new single cell RNA 
sequencing and functional in vitro studies to determine the role of different populations in 
this niche. As we originally intended, it would be interesting to see the single cell RNA 
sequencing profile of AS endometrium so we can compare endometrial regeneration in health 
and disease and understand the pathology of the disease on a molecular level. In doing so, 
our data may provide novel targets for therapeutic intervention.  
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